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ABSTRACT 
YANG LIU: Pharmacokinetics and Biodistribution of LCP Nanoparticles 
(Under the direction of Leaf Huang, Ph.D.) 
Lipid/Calcium/Phosphate (LCP) nanoparticles (NPs) with a well-defined lipid 
bilayer-core structure are effective in encapsulating nucleic acid and silencing target genes in 
tumor cells following systemic injection. The pharmacokinetics and biodistribution of LCP 
NPs was investigated by using nanoparticles containing a tritium-labeled oligonucleotide and 
H460 human lung cancer in a xenograft mouse model. LCP NPs displayed a biphasic 
clearance profile. Approximately 5% and 25% of the injected dose was observed in the tumor 
and liver, respectively. Confocal microscopy showed that LCP NPs localized within 
hepatocytes while Kupffer cell uptake was avoided. Small angle neutron scattering (SANS) 
and fluorescent polyethylene glycol (PEG) quantification data suggested that 20% (mol ratio 
of outer lipids) PEG was grafted on the surface of LCP NPs with an entangled and collapsed 
conformation. Further, it was demonstrated that the delivery to hepatocytes was PEG 
concentration and surface lipid dependent. LCP NPs could be redirected to the 
reticuloendothelial system (RES) from hepatocytes by decreasing PEG concentration on the 
particle surface. LCP NPs with 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) 
exhibited higher accumulation in the liver than LCP NPs with Dioleoylphosphatidylcholine 
(DOPC). Analysis of NPs-bound proteins revealed that apolipoprotein E (apoE) might serve 
iv 
as an endogenous targeting ligand for LCP-DOTAP NPs, but not LCP-DOTAP NPs. The 
enhanced liver accumulation with LCP-DOTAP NPs was reduced in apoE deficient mice. In 
all, characteristics of surface chemistry played important roles in influencing PK and 
biodistribution of LCP NPs. The significant hepatocytes uptake is of great interest to 
formulation design for oncologic and hepatic applications.  
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INTRODUCTION 
 
Intravenously injected nanoparticles (NPs) as drug carriers provide a wide range of 
unique opportunities for site-specific delivery of therapeutic agents to many targets, for 
example tumors or the liver [1, 2]. The future of this expanding field is promising; over 20 
NP therapeutics have been approved by the FDA for clinical use and many are in late-phase 
clinical trials [1, 3]. Safe and efficient delivery of cargos is a precondition for a successful 
nanoparticle-based therapy. Over the past decades, a wide range of nanoparticulate systems, 
such as liposomes and polymeric nanoparticles, have been used as carriers for the 
intravenous delivery and site-specific targeting of small molecules and macromolecular (e.g., 
proteins, nucleic acid) therapeutic agents. Various attempts to increase the therapeutic index 
of drugs while simultaneously minimizing side effects have been made in the field of drug 
delivery systems. 
1.1 BARRIERS FOR DRUG DELIVERY BY NANOPARTICLES 
In general, nanoparticles (NPs) refer to solid, colloidal particles that range from 10 to 
1000 nm in size. To be used as drug carriers, the cargo is dissolved, entrapped, adsorbed, 
attached or encapsulated in the nanostructed material [4]. Nanoparticle therapeutics possess 
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desirable features for medical applications including (i) protection of cargo drugs from 
enzymatic or hydrolytic degradation, (ii) increased solubility and drug loading capacity, (iii) 
sustained and controlled release of drugs, and (iv) preferential accumulation at the site of 
interest through the enhanced permeability and retention (EPR) effect [5]. Despite these 
advantages, injected NPs must overcome both kinetic and physical barriers after 
administration. This is especially true for biopharmaceutical products — that is, peptides, 
proteins and nuclei acids. After the nanoparticle formulation is injected into a periphery vein 
it must protect the cargo molecules from enzymatic degradation by endogenous nucleases. 
The formulation should also avoid aggregation with both blood and extracellular elements 
and the subsequent uptake by phagocytes (Figure. 1.1a). This can be accomplished by 
PEGylation which will be discussed in more detail below. The nanoparticles navigate in the 
bloodstream and then travel to the lung, which contains the first capillary bed as an initial 
mechanical filtration barrier [6].  Large or highly positively charged nanoparticles are 
trapped in the lung [7, 8]. If the nanoparticles are small enough and neutrally or negatively 
charged, they will leave the lung and enter into the systemic circulation, where they would 
encounter all the tissues. The nanoparticles must have a hydrodynamic diameter larger than 
10 nm to avoid rapid clearance from the body via renal filtration and urinary excretion. 
Extravasation from the bloodstream poses a significant challenge to nanoparticle delivery to 
many tissues. Molecules larger than 5 nm in diameter cannot readily cross the capillary 
endothelium and, therefore, will remain in the circulation until they are cleared from the body 
[9]. However, there are certain tissues, including the liver, spleen, and tumor, that allow the 
passage of molecules up to 200 nm in diameter (Figure. 1.1b) [10]. After crossing the 
vascular endothelial barrier and gaining access to the target cells, the nanoparticles have to 
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face a series of physical barriers. Macromolecules such as siRNA cannot cross the cell 
membrane easily owing to its relatively large size and high negative charge content. NPs, 
especially with ligand, can bind and trigger endocytosis to cross the cell membrane and enter 
into their action site— cytoplasm (Figure. 1.1c). More importantly, NPs must escape the 
endosome (Figure. 1.1d); if they do not, they will traffic through the endomembrane 
compartments of decreasing pH and finally be subjected to degradative conditions in the 
lysosomes [11]. Finally, encapsulated drugs must dissociate from the delivery carrier and be 
released to be bioavailable (Figure. 1.1e). 
The RES is a component of the immune system, which utilizes circulating 
macrophages, monocytes, liver Kupffer cells, spleen and other lymphatic vessels to remove 
foreign material, such as bacteria and viruses, from the body. Because bacteria and viruses 
have the same negative surface charge as phagocytic cells, opsonins are critical to reducing 
the charge repulsion between the two systems. Phagocytic cells engulf the foreign material 
once the charge repulsion has been reduced, and transport it to the liver or spleen for further 
degradation and excretion. Additional phagocytic macrophages are permanently located in 
the liver, known as Kupffer cells. These cells serve as a major “first pass” filter for many 
types of NPs and interfere significantly with long circulating time. 
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Figure 1.1 Kinetic and physical barriers to the systemic delivered nanoparticle 
formulation.  
(a) NPs should avoid filtration, degradation and RES uptake in circulation; (b) across the 
vascular endothelial barrier; (c) be internalized into the cells; (d) escape the endosome; (e) 
disassemble and release the cargo. 
1.2 FACTORS AFFECTING PK AND BIODISTRIBUTION OF THE NP 
The biological performance of intravenously injected nanoparticles (PK, tissue 
distribution, therapeutic efficacy and toxicities) is controlled by a complex array of 
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interrelated physicochemical and biological factors. Biological determinants include the 
biochemical, anatomical, and immunological barriers, as well as the opportunities offered by 
disease sites for nanoparticlate therapeutics, as described in sections 1.1 and 1.2.1. The 
influential physicochemical factors include, but are not limited to the size distribution of 
NPs, the particles’ surface characteristics, particle rigidity, and molecular architecture. These 
factors are all tunable parameters and could interact with biological barriers in vivo. Indeed, a 
detailed knowledge of particle characteristics would be vital for design optimization.  
1.2.1 Effect of size 
           On the basis of physiological parameters such as hepatic fenestrae, blood vessel 
extravasation and kidney excretion, it is now well accepted that particle size is a key factor in 
determining the biodistribution of long-circulating NPs and achieving therapeutic efficacy. 
The hydrodynamic diameter of a NP is inversely related to its renal clearance. Particles with 
a hydrodynamic diameter smaller than 6 nm are rapidly cleared by the kidney; an increase in 
particle diameter can significantly increase the half-life of these particles in the blood. 
Additionly , the interaction between NPs and RES in the liver and spleen also plays a critical 
role in nanoparticle clearance. Clearance from the RES depends not only on particle size but 
also on surface modification, which will be discussed in section 1.2.2. Current studies 
suggest that the size of NPs have a substantial effect on protein absorption [12]. Therefore, 
the PK and biodistribution profiles vary significantly among NPs of different sizes. 
Nevertheless, it has been consistently shown that PEGylated NPs smaller than 100 nm have 
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reduced plasma protein adsorption on their surface and a reduced amount of RES uptake 
[13].  
The limited pore size of the endothelial wall in the tissue is the primary delivery 
barrier for NPs but also provides the opportunity for selective accumulation in certain tissues. 
Unlike small molecule drugs that can penetrate through the capillary wall into the tissue by 
passive diffusion, NPs rely on a discontinuous endothelium to pass through the barrier. The 
major pathway of extravasation of nanoparticles is through leaky blood vessels with 
increased permeability. Tissues with leaky endothelial walls, including tumors, the liver, 
spleen, and bone marrow, usually have an increased uptake of NPs. A NP diameter less than 
100 nm is required for entry into the hepatocytes due to the presence of fenestrae in the liver 
sinusoidal endothelium, which have an average diameter of 100 nm [14, 15].  Relatively 
larger particles (100-200 nm) accumulate in the tumor site through the enhanced EPR effect 
[16]. Tumor endothelium is often disorganized and does not have a basement membrane. 
Nanoparticles can penetrate into the tumor parenchyma and be retained, a phenomenon that 
can be at least partially explained by the lack of lymphatic drainage in the tumor [16]. 
However, the degree of leakiness of the tumor endothelium, and consequently the optimal 
size of the nanoparticles, varies significantly among different tumor types [17]. For example, 
the vasculatures in human brain, pancreatic and ovarian cancers are known to be less leaky 
than those of other cancers [18, 19]. 
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1.2.2 Effect of surface characteristics 
Opsonization is the major factor that induces RES uptake of NPs. However, the 
surface characteristics of the NPs can counteract the hydrophobic and electrostatic 
interactions between the NPs and the plasma proteins or macrophages, resulting in less RES 
uptake and a prolonged blood circulation time. Therefore, surface characteristics of NPs 
greatly influence their PK and biodistribution. NPs that have a mean diameter of 
approximately 100 nm with a neutral and hydrophilic polymer-modified surface generally 
exhibit a prolonged blood circulation and an increased level of tumor delivery. 
1.2.2.1 Effect of surface chemistry 
It has been reported that surface charge is a very important factor in determining the 
in vivo fate of NPs, as well as the mechanism of cellular uptake and resulting efficiency [20, 
21].  Surface charge is usually introduced onto certain types of NPs (such as iron oxide and 
gold) to improve stability and prevent further aggregation of the particles in aqueous solution 
via the electrostatic repulsion [22]. However, the optimum surface charges (i.e. positive, 
neutral or negative) and charge densities, which may prolong the blood circulation time and 
minimize the nonspecific and undesired distribution of NPs, vary significantly among 
different nanoparticle systems. These variations might be attributed to the nature of charged 
groups, the difference in stability of the NPs, and other confounding factors such as particle 
sizes that are not uniform. A correlation between surface charge (typically net positive) and 
opsonization has been demonstrated in vitro [23]. Therefore, charge shielding is commonly 
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employed through the introduction of surface coatings in order to reduce opsonization. 
PEGylation technology has been developed to improve the stability, blood circulation time 
and pharmacokinetics of biopharmaceutical agents.  A coating of PEG on the surface of NPs 
has been shown to prevent particle aggregation and reduce the opsonization with serum 
proteins, leading to decreased RES uptake and prolonged circulation time [24-26].  
Although NPs carrying a negative charge may have significantly less non-specific 
uptake in the liver and spleen compared with their positive or neutral counterparts, the 
electrostatic repulsion between negatively charged NPs and cellular surfaces could prevent 
cellular uptake [27, 28]. Many macromolecules cannot easily cross the cell membrane owing 
to their relatively large size and high, negative charge content. Extracellular release is not a 
good design for the delivery of membrane impermeable drugs such as siRNA and proteins. 
This problem might be solved through the creation of NPs with targeting ligands, which can 
bind and trigger endocytosis to cross the cell membrane and enter into their action site.   
1.2.2.2 Effect of active targeting 
It is widely believed that targeted drug delivery using NPs has the potential to provide 
safer and more effective therapies for oncology applications. Passive tumor targeting takes 
advantage of the leakiness of tumor vasculature to allow nanoparticle extravasation and 
accumulation in the tumor site (termed as EPR effect). On the other hand, active targeting 
exploits the overexpression of surface receptors on cancer cells by providing targeting 
ligands that can engage these receptors. Current studies on active targeting have used an 
assortment of ligands ranging from proteins (monoclonal antibodies [29] and their fragments 
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[30]), nucleic acids (i.e. aptamers [31]), and small molecules (e.g. folic acid [32] and RGD 
peptide [33]); the attachment of a targeting moiety on the surface of nanoparticles improves 
their therapeutic outcomes in vivo [34]. However, recent work in understanding the 
parameters that influence targeted nanoparticle behavior has revealed that the presence of the 
targeting ligand does not significantly affect their PK or biodistribution profiles [35-37]. It is 
suggested that the enhanced therapeutic efficacy was attributed to the increased cellular 
uptake of the targeted nanoparticles [36]. Active targeting leads to selective nanoparticle 
internalization into cancer cells that have abundant receptor expression. Furthermore, these 
studies also indicate that there is a minimum density requirement of targeting ligand content 
on the nanoparticle that provides adequate avidity for effective active targeting. 
1.2.3 Other factors 
Other than the topics discussed above, there are several other critical issues that need 
to be considered in achieving desired PK and biodistribution patterns. For example, stability 
is a key issue in the creation of successful pharmaceutical products. The in vivo stability is an 
important prerequisite parameter needed to allow prolonged blood circulation and the 
preferred tissue distribution.  
Shape is another fundamental property of NPs that may be critically important for 
their intended biological functions. Discher et al. (year) have developed worm-shaped 
nanoparticles composed of a diblock copolymers, which can circulate in the blood of mice 
with a surprisingly long half-life ( i.e., 5 days) [38]. Park et al. (year) also observed that 
magnetic nanoworms have a long half-life in vivo [39]. Length and flexibility of these 
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particles may also contribute to their long circulation times. Additionally, studies utilizing 
cultured macrophages revealed that the worm-shaped nanoparticles experience a strong drag 
force exerted by the fluid flow, enabling them to be carried away by the flow before the 
macrophages can engulf them. This phenomenon is probably the underlying mechanism of 
the nanoworms’ extremely prolonged circulation time.  Mathematical models have been 
developed to study the adhesion properties for NPs of various shapes; Decuzzi and Ferrari 
(year) concluded that NPs used for drug delivery should have a radius smaller than 100 nm in 
order to facilitate their interaction with the endothelium wall [40]. 
1.3 PEGYLATION: GRAFTING DENSITY AND CONFORMATION 
The success of PEGylation critically depends on the steric stabilization conferred by 
PEG chains on the surface of the NPs. Stabilization is achieved through the highly 
hydrophilic and flexible nature of PEG chains, which provide repulsive interactions with 
biological components in vivo. The ways in which grafted PEG forms a well hydrated barrier 
layer on the surface, sterically hindering protein adsorption, can be described by relatively 
straightforward theories of polymer physics that originated from Flory [41] and De Gennes 
[42].  Surface-grafted PEG adopts two different statistical conformations, “mushroom” and 
“brush,” that are dictated by the relationship between the distance of two grafting sites and 
the radius of the random coil the polymer forms in solution. The brush configuration is 
favored for drug delivery because it ensures that the entire surface of the NP is covered, 
leaving few gaps where opsonin proteins can freely penetrate and bind [25, 43]. Many studies 
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indicate that PEG chains must have a minimum molecular weight of 2000 to achieve RES-
avoidance, making PEG2000 the most frequently used PEG polymer [13, 25, 26]. Essentially, 
the grafting density of PEG chains determines the efficiency of PEGylation and thereby the 
protein repelling capability of the resultant NPs.  
1.3.1 Steric stabilization by PEGylation 
The mechanism by which PEGylation increases circulation times and improves 
biodistribution profiles is not fully understood. However, the most widely accepted 
explanation is that PEG provides a steric barrier, which prevents nanoparticle opsonization, 
which delays removal by the RES. PEGylation involves physical, chemical, and biological 
stabilization of the liposomes and retention of their payload. The conformational flexibility 
and high chain mobility of PEG lead to extensive hydration in aqueous environments, 
causing a steric hindrance to protein adsorption. Thus, such polymers shield the hydrophobic 
surface of the particles and thereby reduce opsonization by blood proteins and uptake by 
macrophages of the RES.    
In addition to clearance by the RES, aggregation caused by NP-NP interactions may 
also lead to poor in vivo performance. NPs with a high surface energy have a greater 
tendency to aggregate, primarily because the attraction between particles is stronger than 
their attraction to the solvent [44]. The interaction potential of spherical NPs is related to 
their electrostatic repulsive potential and their van der Waals attraction potential. PEGylation 
decreases the surface energy of NPs and minimizes van der Waals attractions [45]. 
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1.3.2 Conformation of surface-grafted PEG 
 Experimental data closely follows the theoretical model that protein repellence by 
PEG coatings depends on both length and density of the chain which jointly determine the 
thickness of the PEG corona. The conformation of surface grafted PEG chains is dictated by 
the relation between the distance of two grafting sites (D) and the radius of  the random coil 
the polymer forms in solution (RF), the latter being defined by the Flory dimension (RF = 
aN3/5), where N is the degree of polymerization and a is the monomer size [46]. The polymer 
forms a mushroom conformation at D > 2RF, while a brush-like conformation appears at D < 
RF, when the polymer chains stretch out perpendicularly from the surface due to steric 
hindrance among each other (Figure 1.2a).  These two conformations do not represent 
sharply separated regimes, but undergo smooth transitions through mushroom/brush 
intermediates as D and RF values became closer [47]. The transition between the mushroom 
and brush regimes occurs at the concentration of grafted PEG-lipids (Xm-b) where the PEG 
chain first begins to overlap as random coils (i.e. mushroom).  This concentration is 
determined by the size of the polymer (RF).   
An increase in PEG:mole fraction or density can lead to a significant increase in the 
circulation half-life of the NPs, a consequence of reduced protein binding and opsonization 
[26]. However, PEG–lipid conjugates are detergent-like surfactants which tend to form 
mixed micelles with other lipids, thus they can only stably incorporate as a small mole-
fraction of any lipid membrane [48-50].  In this low mole-fraction (usually less than 5 
mol%), the polymer chains adopt a mushroom conformation. Density and thickness of the 
PEG corona cannot provide full protection of the hydrophobic surface from opsonization, as 
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shown in Figure 1.2a. Li & Huang employed PEGylated liposome-polycation-DNA (LPD) 
NPs to address this issue (citation). In that formulation, the nucleic acid was complexed by 
protamine to form a compact core, which was coated by two cationic lipid-bilayers. The 
inner bilayer is directly in contact with the core and is supported and stabilized by the charge-
charge interaction of the cationic lipids with the negatively charged core. This unique feature 
of LPD may enable the supported bilayer to tolerate a high amount of DSPE-PEG2000 (10 mol 
%), forming a relatively dense PEG brush on the surface [51]. As a result, the zeta potential 
of an unprotected LPD is +40 mV, while a fully protected LPD contained 10 mol% surface-
grafted PEG has a zeta potential of approximately 0 mV. LPD containing 10 mol% PEG was 
not taken up by the liver Kupffer cells, thus completely evading the RES [52, 53]. Of course, 
the accumulation in the tumor still depends on how leaky the tumor vasculature is, i.e., the 
EPR effect. 
Our recent studies also showed that small nanoparticles require a higher amount of 
PEG-lipids to avoid RES uptake (data unpublished).  In other words, Xm-b (the concentration 
of grafted PEG-lipid for which the PEG chains first begin to overlap) increases with 
decreasing particle size. On the surface of a small particle, each PEG-lipid molecule can 
occupy a larger volume than if it is on a flatter surface (Figure 1.2b). This is due to the high 
curvature of a small particle. Consequently, the PEG chains exert less steric interactions (i.e. 
excluded volume effects) and tend to appear in the less compact and less dense mushroom 
conformation. To assure a brush-like conformation of the coating, the amount of PEG-lipid 
conjugate should be increased. The Flory radius for PEGs of molecular weight 750, 2000 and 
5000 is RF = 2.1, 3.8 and 6.7 nm, respectively [46]. Since the size of commonly used 
nanoparticles is usually around or larger than 100nm, the curvature effect is of little 
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significance.  As the particle size decreases, its influence will need to be taken into 
consideration. Xm-b will be determined by the size of PEG-lipids (RF) as well as the radius (r) 
of the nanoparticle on which they are grafted.   
 
Figure 1.2 Putative PEG conformation regimes with respect to the polymer 
concentration in (a) the bilayer and (b) the curvature of the bilayer.  
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1.3.3 Linkage of PEG to NPs 
Both covalent and noncovalent approaches are used to anneal PEG molecules to the 
NP surface. In the creation of solid NPs, such as gold NPs, a thiol group is the classic 
approach. Here, a sulfhydryl-capped PEG chain adheres to the gold surface [54]. Silica NP 
surfaces are generally capped with an organosilane such as amino- or mercapto-
trimethoxysilane for routine bioconjugation [55].  
A commonly used approach in noncovalent PEGylation involves coating the 
hydrophobic NP surface with lipid–PEG conjugates through hydrophobic interactions. For 
example, to prepare PEGylated liposomes, it is feasible to simply include PEGylated lipids 
into the lipid mixture, or incubate naked liposomes with aqueous micellar solution of lipid–
PEG conjugates [56]. PEGylated phospholipids are able to bind to the hydrophobic surface of 
NPs, for example single-walled carbon nanotubes [57], hydrophobic polymeric NPs [58], or 
quantum dots [59], in such a way that hydrophilic PEG groups are facing the aqueous 
exterior and provide the nanotubes with a hydrophilic PEG corona. The hydrophobic 
interactions between lipids and NPs anchor the PEG chain.  
1.3.4 Coverage density and conformational studies 
PEG density on the nanoparticle surface has been found to be a critical factor in 
modulate nanoparticle behavior in vivo and in nonspecific cellular uptake. To date, there is 
no direct method available for quantifying the number of PEG molecules bound to a NP 
surface or for determining the density of PEG [60]. Many reports simply assume a complete 
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loading of added PEG molecules to determine the density. Thus, the exact influence of PEG-
density dependence on NP biodistribution remains unknown. 
Dynamic light scattering reveals three important characteristics of the final 
PEGylated NPs: size, zeta potential and size distribution. Size measurement by dynamic light 
scattering suffers from poor reproducibility, yet it is convenient and can be used to monitor 
the sequential size increases which occur before and after PEGylation [61]. The size 
distribution can be used to measure the homogeneity of the NPs. Although size increases 
offer some evidence of PEGylation, it cannot discriminate between brush and mushroom 
configurations. Zeta potential also offers information regarding the surface coating; reduced 
surface charge may indicated the presence of PEGylation. Unfortunately, these 
measurements are suboptimal and inconclusive in determining PEG density and 
conformation.  
Raman analysis offers detailed information on concentration and conformation, but is 
generally beyond the scope of most laboratories [62].  Nuclear magnetic resonance (NMR) is 
a method that is more widely available and is used to detect the ethylene protons at 3.65 parts 
per million, but it is not quantitative [63]. Alternatively, thermal gravity analysis (TGA) has 
also been used to estimate the number of PEG chains on the surface of a nanoparticle. It 
measures the mass change before and after removal of PEG chains by using thermal 
desorption and decomposition. To measure the mass loss accurately, a relatively large 
quantity of the sample is required. The coverage density calculated from TGA data 
corresponds to the total number of PEG chains in the sample, including those loosely trapped 
among the particles. Some groups, including ours, have successfully used fluorescence-
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labeled PEG to model the binding densities possible at different density levels. This approach 
may not be appropriate for gold NPs because of quenching.  
NPs that have a PEG corona adopt a core-shell structure, concentric domains of two 
chemically different materials, a structure that is ubiquitous in the colloid science field. 
Structural information on core-shell systems can be assessed effectively using scattering 
techniques. In particular, they can be studied in great detail using contrast-variation methods 
[64], achieved most readily in the context of small-angle neutron scattering (SANS). Several 
studies have also used light or X-ray scattering. In this work, we use SANS to investigate the 
aqueous dispersions of PEG-grafted, LCP NPs under two different temperatures. We focus 
on how the signals change in relation to increasing temperature. The conformation of grafted-
PEG could be estimated by model fitting the signals. Detailed information of SANS studies 
is provided in APPENDIX A. 
1.4 PROTEIN ADSORPTION ONTO NANOPARTICLES 
1.4.1 Formation of the protein corona 
In comparison to bulk biomaterials, NPs have an extremely high surface-to-volume 
ratio. Control of this, as well as other surface properties, is crucial to the in vivo performance 
of NPs. It is now well-recognized that the surfaces of NPs are immediately covered by 
proteins when they come into contact with a biological medium [65, 66]. The absorption of 
proteins to such surfaces confers a new “biological identity” to NPs in the biological milieu, 
which is what cells, tissues and organs actually “see” when interacting with NPs [67]. This 
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new “bio-nano interface,” created by covering NPs with a complex layer of proteins 
(corona), determines the subsequent cellular/tissue responses and biological consequences 
[68, 69]. Surface characteristics such as charge, hydrophilicity and curvature dictate the 
extent and specificity of protein binding [67, 70]. Specific protein binding is one of the key 
elements that affect biodistribution of the NPs. Indeed, a detailed knowledge of NP-protein 
interaction is vital for a rational formulation design as well as optimization.  
 
1.4.2 Analytical method for corona evaluation 
Analysis of the protein corona involves purification of protein-NP complexes and 
separation and identification of the purified proteins. To date, the routine method for 
isolating protein-NP complexes is centrifugation. Relative to other techniques, centrifugation 
is easy and requires little material. Separation by centrifugation has been used to identify 
major plasma proteins such as human serum albumin (HSA), immunoglobulins, and 
fibrinogen bound to the NPs [66], [71]. It is not surprising to find these proteins bound to 
injected NPs because these are some of the most abundant proteins found in human plasma. 
A common technique for the separation of the proteins is one or two-dimensional 
polyacrylamide gel electrophoresis (1D- or 2D-PAGE). To identify individual proteins, it is 
common practice to conduct mass spectrometry followed by peptide sequencing on 
individual excised protein spots from the 1D or 2D gel and compared to a known database of 
proteins [72]. For the identification of particular proteins of interest, immunoblotting and 
Western blotting have also been applied [73]. 
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Aside from gel electrophoresis, other separation methods involving gel filtration, such 
as size-exclusion chromatography or affinity chromatography, are also used to separate 
proteins from plasma and identify individual proteins [66].  
1.4.3 Outcome of protein-NP interactions 
While the complete plasma proteome is expected to contain as many as 3700 proteins 
[69], of which only approximately 50 have been found in the protein corona associated with 
nanoparticles [67, 74]. Specific protein binding can have a direct effect on biodistribution 
and internalization of NPs. Certain components of the corona proteins allow macrophages of 
the RES to easily recognize NPs. These proteins are knownas “opsonins.” Binding of 
opsonins, for example, fibrinogen, Immunoglobulin G (IgG), and complement factors, are 
believed to promote phagocytosis and the removal of the particles from systemic circulation 
via cells of the RES. These particles tend to sequester in the RES organs very rapidly and 
concentrate in the liver and spleen. On the other hand, dysopsonins such as HSA generally 
prolong circulating time in the blood [75].  
Apolipoprotein adsorption has been reported with various NPs. Its biological 
significance presumably depends on the conformation of apolipoproteins and the exposure of 
functional motifs that may serve as ligands for lipoprotein and scavenger receptors expressed 
by macrophages, hepatocytes and vascular endothelial cells [76, 77]. It was reported that 
specific apoE binding to NPs may facilitate delivery across the blood brain barrier (BBB) 
into the brain, and the adsorption of apolipoproteins has been shown to be important for the 
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transportation of drugs across the BBB and into the brain, though the mechanism of transport 
is still under debate [78]. 
To inhibit opsonization and subsequent clearance by the RES, the surface of the NPs 
can be coated by hydrophilic polymers such as PEG to reduce protein binding [79-83]. The 
mechanism by which PEG decreases protein interactions is non-specific [84]. PEG is not the 
only polymer that can be attached to NPs to inhibit the protein binding to the surface of the 
NPs and avoid immune recognition. Various other polymers and polysaccharides have been 
utilized in place of PEG. In all cases, protein adsorption was not completely avoided (i.e. 
HSA, fibrinogen, IgG, and apolipoproteins were detected), but was greatly reduced [72].  
1.5 PERSPECTIVES OF OPTIMIZING IN VIVO PERFORMANCE OF NP 
Outcomes from studies completed in the past decade regarding the biological 
responses to nanomaterials have greatly influenced design of nanoparticle therapeutics. 
Material design evolved whenever the effect of size, shape, or surface chemistry was further 
elucidated. Currently, the engineering of NPs for biomedical applications has been focused 
on novel nanomaterials functionalized with optimized surface chemistries that improve 
stability, bioavailability and biocompatibility. This approach, however, has encountered 
certain limitations. First, there appears to be an overreliance on the EPR effect to deliver NPs 
into tumors, when the efficacy of this phenomenon might be highly variable amongst 
different tumors and individual patients. Second, there is no single property of NPs that can 
be optimized to ensure efficient delivery, as NPs have to travel through multiple, distinct 
barriers in the body.  
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Responding to these limitations, researchers recently shifted the paradigm of design 
from stable nanomaterials to “environment-responsive” systems that possess stimuli-
responsive properties. External stimuli cause changes in the particle size, shape or surface 
structure, and lead to their rearrangement to improve targeted compound delivery. These 
dynamic nanoparticle systems may use biological, physical, or chemical factors in their target 
environment to trigger a change in their properties to maximize targeted delivery. Two 
approaches have been used so far. The first uses hallmark cues inside the target environment 
such as low pH, low O2 and ormatrixmetalloproteinase enzymatic activity within the tumor. 
One example is NPs with a PEG surface layer that will shed off in response to pH to reveal a 
positively charged surface. These particles target and are retained in hypoxic tumor regions 
[85]. Other groups have used pH to trigger the breakdown of the NPs to release drugs in local 
tumor environment [86]. Enzymatic activity has also been used as a trigger for drug release 
[87]. Additionally, by using local cues inside the tumor to trigger drug release, the NPs 
localized in the liver and spleen do not cause toxicity.  
Alternatively, a multistage nanoparticle delivery system was designed with the ability 
to change size, triggered by proteases that are highly expressed in the tumor 
microenvironment (e.g. matrix metalloproteinases (MMP)). The enzyme degrades the cores 
of 100 nm gelatin NPs, releasing smaller 10 nm quantum dots from their surface. The 
rationale of this design lies in that many of the current nanotherapeutics are designed to be 
around 100 nm in diameter to exhibit enhanced accumulation around the leaky vasculature in 
the tumor. Their large size, however, hinders penetration through the dense extracellular 
matrix. Therefore, a multistage system in which 100 nm NPs “shrink” to 10 nm NPs after 
they extravasate from leaky regions of the tumor vasculature and are exposed to the MMP-2 
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in tumor microenvironment maximizes tumor delivery. The shrunken NPs can more readily 
diffuse throughout the tumor for improved diagnostic sensitivity [88]. The second approach 
applies an artificial environmental cue such as near-infrared (NIR) light upon the target 
tissue. The NIR light can excite gold nanorods or nanoshells inside the tumor to generate heat 
to trigger localized drug release from the liposomes [89, 90].  
Recently, inspired by the ability of communication to improve targeting in biological 
systems (e.g. inflammatory-cell recruitment to sites of disease), the concept of 
“communicating nanoparticles” was broached. The “locator particle” is a gold nanorod, 
which extravasates through the abnormally large pores of tumor blood vessels. Subsequently, 
infrared light is applied to heat up enough to initiate the coagulation cascade. Here, the 
“receiver particle”, which is designed to target specific molecules produced by the 
coagulation process at a high concentration, comes into play. In this way, the “locator 
particle” broadcasts tumor location to the clot-targeted “receiver particle” in circulation, 
thereby amplifying the tumor delivery of both. This approach does not overly rely on the 
EPR effect and can deliver doses of chemotherapeutics to tumors that are over 40 times 
higher than those delivered by non-communicating controls [91]. 
 CHAPTER 2 
METHODOLOGY FOR PK / BIODISTRIBUTION STUDIES 
 
The biodistribution of LCP NPs in tumor-bearing mice was investigated using 
fluorescence imaging. A quantitative validation of this method was done using 3H and 111In 
to label the nanoparticles. The biodistribution of LCP NPs containing oligonucleotides was 
investigated using three different probes: Texas-Red labeled oligonucleotides, 3H-labeled 
oligonucleotides, and 111In-labled calcium phosphate. A discrepancy was found between the 
radioactivity and the fluorescence signals. Signals from 3H and 111In exhibited very similar 
distribution patterns, suggesting that the liver and spleen were the major accumulation sites. 
However, fluorescence imaging indicated that tumor accumulation was predominant. We 
confirmed that the fluorescence signals in both liver and spleen were less than those in the 
tumor due to the intrinsic tissue absorption and scattering. The use of NIR dye Cy5.5 brings 
about the same problem, in that the quantitative data from whole organs was dramatically 
affected by the absorption and scattering properties of the tissue. Careful attention must be 
paid to the quantification and interpretation of fluorescence imaging measurements when 
comparing different tissues. The following PK and biodistribution studies were performed 
using LCP NPs containing 3H-labeled oligonucleotides. 
  
2.1 INTRODUCTION 
The use of therapeutic macromolecules such as oligonucleotides has been intensively 
studied for the treatment of several major disorders. A key issue in the successful 
development of  these therapies is to understand and control the biodistribution of 
macromolecules [92].  PK and biodistribution studies can provide invaluable information 
early in the development. This importance has created a need for techniques that can analyze 
the macromolecules qualitatively. Traditionally, biodistribution studies of macromolecules 
were carried out in animals by measuring the radioactivity associated with the drugs [93, 94]. 
Mass spectrometry methods have also been developed to study the biodistribution of drugs, 
which allows for both quantiﬁcation and identiﬁcation of the analyte [95]. Obviously, 
radioactive compounds are a potential health hazard and environmentally unfriendly. 
Synthesis and disposal of radioactive compounds are expensive. For some isotopes with 
relatively short half-lives, radioactivity decay is quite rapid and thus, the compounds lose 
their usefulness in time. Mass spectrometry (MS) is now playing a central role in PK and 
biodistribution studies. Advances in ionization methods, including electrospray ionization 
(ESI) and matrix-assisted laser desorption/ionization (MALDI), have expanded the use of 
MS in investigating macromolecular drugs. However, successful MS measurement relies on 
target molecule extraction/isolation from biological specimens, which can be complicated 
[96]. Many labs still cannot readily access the resources and expertise required for this 
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method. In addition, mass spectrometry is an end-point measurement, which lacks the ability 
to probe dynamic events in real time.  
Due to the aforementioned circumstances, fluorescence imaging is emerging as a 
popular modality to couple with the traditional methods. Fluorescent dyes are conjugated to 
the drug to produce optical probes used in vivo or ex vivo. This technology is relatively safe, 
low-cost and noninvasive. The key to effective imaging, especially in deep tissues, is the use 
of ﬂuorophores with a red or NIR emission range (600–1000 nm), which corresponds to low 
photon absorption and auto-fluorescence in tissues. Biological chromophores, in particular 
hemoglobin, strongly absorb visible light, thereby limiting the penetration depth to only a 
few millimeters. Other biological components, such as water and lipids, are optically 
transparent from the visible to the NIR range, but strongly absorb light in the infrared. The 
combined absorption of these components translates into an optical imaging window of 
approximately 600 to 1000 nm where the absorption coefﬁcient of tissue is at a minimum. 
Additionally, light scattering and auto-ﬂuorescence are low in the NIR. This allows a 
significant signal with relatively low background [97, 98].  
Many researchers, including ourselves, have used fluorescence imaging to assess the 
biodistribution of nanoparticles loaded with fluorescence-labeled drugs [99-102]. This 
method gives an indication of tissue accumulation patterns, which facilitates the design and 
optimization of the formulation. Although most of these studies quantified the biodistribution 
based on the fluorescence intensity, the validation of this method in a variety of tissues has 
not yet been studied systematically. Here, we investigated the biodistribution of LCP NPs 
containing oligonucleotides using three different probes: 1) Texas Red labeled 
oligonucleotides; 2) 3H-labeled oligonucleotides; and 3) 111In, which can form co-precipitate 
with calcium phosphate, and was used as a radiotracer for the intact LCP NPs. LCP contains 
 25 
an amorphous, calcium-phosphate-precipitate core wrapped with a single lipid-bilayer with 
surface modification of polyethylene glycol with and without a targeting ligand [99]. The NP 
formulation has been successfully used to deliver siRNA [99, 103] and cDNA (unpublished 
results) to both solid and metastatic tumors. Our results showed a discrepancy between the 
radioactivity and the fluorescence signals. Signals from 3H and 111In exhibit very similar 
distribution patterns, suggesting that the liver and spleen were the major accumulation sites. 
However, fluorescence imaging indicated that tumor accumulation was predominant. 
Furthermore, we found that the fluorescence signals in both liver and spleen are greatly 
attenuated compared with those in the tumor due to the intrinsic tissue absorption and light 
scattering.  Therefore, careful attention must be paid to the quantification and interpretation 
of fluorescence imaging measurements, which could skew the data towards the tissues with 
less light absorption and scattering.  
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
22-mer oligonucleotides (sense sequence, 5’-CAAGGGACTGGAAGGCTGGG-3’,) 
labeled with Texas Red or Cy5.5 Dye (excitation/emission wavelengths of 550/600 nm and 
650/700nm, respectively), were purchased from Sigma, Inc. Both Texas Red and 3H-labeled 
oligonucleotides were used to mimic siRNA. Dioleoylphosphatidylcholine (DOPC), 
dioleoylphosphatydic acid (DOPA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[poly(ethylene glycol)2000] (DSPE-PEG2000) were purchased from Avanti Polar Lipids, Inc. 
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(Alabaster, AL). NCI-H460 human lung cancer cells were obtained from American Type 
Culture Collection.  
2.2.2 Experimental animals  
All animal work was performed in accordance with and approved by the University 
of North Carolina Institutional Animal Care and Use Committee guidelines.  Athymic nude 
(nu/nu) mice carrying H460 human lung cancer xenografts were used for all of the 
experiments. 
2.2.3 3H labeling of oligonucleotides 
3H labeling of oligonucleotides was prepared by inducing hydrogen exchange with 
3H2O at the C8 positions of purine oligonucleotides using methodologies described by 
Graham et al. [104]. For each labeling experiment, 12 mg of 22-mer oligonucleotide was 
dissolved in 200 μL of 50 mM sodium phosphate and 0.1 mM EDTA (pH 7.8) and 
lyophilized in a 2 mL glass microfuge tube. The dry oligonucleotide was resuspended in 200 
μL of 3H2O (Moravek, specific activity 5 Ci/gm) containing 8.3 μL of the free radical 
scavenger, β-mercaptoethanol. The sample was incubated at 90°C for six hours. Following 
the incubation, the sample was lyophilized to remove 3H2O that had not been exchanged. The 
sample was resuspended in 1mL water and allowed to rest at room temperature for one hour 
to enable the exchangeable protons to dissociate rapidly. The period of incubation at room 
temperature was followed by four cycles of lyophilization and subsequent resuspension in 
0.5 mL of water. The labeled oligonucleotide was then purified using a spinning column 
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containing Sephadex G-25 (GE Healthcare, Life Sciences). The radiolabeled compound is 
stable in biological systems and was stored at -20°C for further experiments.  
2.2.4 Preparation of LCP NPs 
LCP NPs were prepared according to the method described previously with minor 
modifications [99]. We first prepared two water-in-oil microemulsions: 1) 100 μL of 500 
mM CaCl2 and 16 μL of 2 mg/mL Texas Red or 3H-labeled oligonucleotides in 8 mL 
cyclohexane oil phase (71% cyclohexane with 29% Igepal CO-520 as surfactant) and 2) 100 
μL of 100 mM pH 9.0 Na2HPO4 also in 8 mL cyclohexane oil phase plus 320 μL of 20 mM 
DOPA as the inner leaflet lipid. 111In-loaded nanoparticles were created by adding 
radioactive InCl3 (in 0.05 N HCl, PerkinElmer, Inc.) to the CaCl2 microemulsion, as a 
sufficient amount of 0.05 N NaOH was added to the Na2HPO4 microemulsions to neutralize 
the acid. After mixing the two solutions for 45 min, 30 mL of absolute ethanol was added to 
the micro-emulsion and the mixture was centrifuged at 12,500 g for 15 min to precipitate the 
CaP (or CaP/In) cores. After being washed extensively with ethanol 2–3 times, the pellets 
were dispersed in 500 μL chloroform and stored in a glass vial for further modification. For 
outer leaflet lipid coating, 200 μL of 20 mM cholesterol, 200 μL of 20 mM DOPC, and 100 
μL of 20 mM of DSPE-PEG2000 were mixed with the core. After removal of the chloroform, 
the core was first suspended in a small volume of ethanol, and then dispersed in an aqueous 
solution containing 5% dextrose.  
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2.2.5 Tissue distribution study by Texas Red labeling 
LCP NPs containing Texas Red-labeled oligonucleotides were intravenously injected 
into the tumor-bearing mice at a dose of 0.25 mg/kg of oligonucleotides. Four hours later, 
mice were sacrificed and tissues of interest were collected for fluorescence imaging. 
Fluorescent images were acquired under the IVIS Imaging System (Xenogen Imaging 
Technologies, Alameda, CA) at indicated wavelengths. 
2.2.6 Tissue distribution study by radioisotope labeling 
A dose of 0.25 mg/kg of oligonucleotides of labeled LCP NPs was intravenously 
injected into the mice. Four hours later, mice were sacrificed and tissues of interest were 
collected for further analysis. The amounts of 3H-labeled oligonucleotides and 111In that 
accumulated in different tissues were quantified using liquid scintillation and gamma 
counting, respectively. 
2.2.7 Fluorescence intensity measurement in different tissues 
Un-injected animals were euthanized and their blood was collected using cardiac 
puncture. The livers, spleens and tumors of these mice were also harvested. To measure the 
fluorescence intensity in whole organs, 0.25 µg of Texas Red labeled oligonucleotides were 
directly injected into the livers, spleens and tumors of the mice using a Hamilton syringe. To 
measure the fluorescence intensity in tissue homogenate, tissue samples were weighed and 
placed in a homogenization buffer (10 mM Tris pH 7.4 and 0.5% Triton X-100) at a ratio of 
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100 mg of tissue per mL. One-hundred μL each of blood, tissue homogenate and 
homogenization buffer were then transferred to a 96 well plate. Ten μL of homogenization 
buffer containing various amounts of Texas Red oligonucleotides were added. The tissues 
and plate were then imaged using an IVIS Imaging System as described above. The plate was 
also measured by a plate reader (Bioscan Inc., Washington DC) for the fluorescence intensity 
in order to create standard curves. 
To prepare the perfused liver, un-injected animals were euthanized and 3 mL of warm 
PBS was perfused via portal vein through the liver to expel the blood. The perfusion rate was 
kept at about 3 mL/min. Texas Red-labeled oligonucleotides (0.5 µg) were directly injected 
into non-perfused liver, perfused liver and tumor, respectively. The tissues were then imaged 
using the Kodak In Vivo Imaging System FX Pro (Carestream Health, Woodbridge, CT) at 
indicated wavelengths.  
2.2.8 Statistical analysis 
Data are presented as the mean ± SD.  The statistical significance was determined by using 
the two-sided student t-test.  P values of <0.05 were considered to be significant. 
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Figure 2.1 Formation of LCP NPs formulation in microemulsion. 
2.3 RESULTS  
We investigated the biodistribution of LCP NPs in tumor-bearing mice using Texas 
Red, 3H and 111In labeling. 3H labeling revealed that significant accumulation of the 
nanoparticles occurred in the liver (30% injected dose (ID)) and the spleen (15% ID), while 
only 5% ID was found in the tumors (Figure 2.2A). Consistent with the 3H data, around 20% 
ID and 15% ID of 111In were found in the liver and spleen, respectively (Figure 2.2B).  Less 
than 5% ID was seen in the tumor. The agreement between the labeling of the drug (3H-
oligonucleotides) and that of the drug carrier (111In) suggested that this biodistribution pattern 
may accurately represent the in vivo behavior of LCP NPs. However, as shown in Figure 
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2.2C, significant fluorescent signals could be detected in the tumors, while the brightness of 
the liver and spleen remained just above the background level. To test whether fluorescence 
intensity of labeled oligonucleotides is subjected to the microenvironment in which they 
reside, the liver, spleen and tumors were dissected from un-injected animals and directly 
injected with fluorescence-labeled oligonucleotides. The ex vivo fluorescence imaging is 
shown in Figure 2.3A. Minimal signals were detected in the liver and the spleen. In contrast, 
the tumor showed significant fluorescence. These results suggested that tissue characteristics 
in the liver and the spleen strongly influences and reduced the fluorescent signals.  
Whole blood and tissue homogenate were then used to study the fluorescent signal 
linearity and reduction effect in different organs. As Figure 2.3B shows, when equal 
amounts of Texas Red-labeled oligonucleotides were added, the intensities in the tumor 
homogenates and buffer were higher than those in whole blood, liver and spleen 
homogenates. By adding 15 μl of whole blood to 100 μl of tumor homogenate, the 
fluorescent signal was greatly diminished.  These results suggested that blood played an 
important role in reducing the Texas Red signals from tissues, the phenomenon can be 
explained by the fact that hemoglobin has its secondary absorption peak between 550nm and 
600nm. Therefore, the sensitivity of the Texas Red probe could be greatly hampered in 
blood-enriched tissues such as the liver and spleen. Using the liver perfusion technique, the 
role of blood hemoglobin in reducing the Texas Red signal was further elucidated. The 
results are shown in Figure 2.3C. As the perfused mouse liver contained less blood, when 
injected with the same amount of Texas Red-labeled oligonucleotides, it emitted stronger 
fluorescence than the non-perfused liver. We demonstrated that a similar problem also 
existed in using a NIR probe. With equal amounts of Cy5.5 dye, the intensities in the tumor 
homogenate and buffer were higher than those in whole blood and the liver homogenate 
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(Figure 2.4). These differences should be taken into account in the quantitative analysis of 
biodistribution data. Texas Red-labeled oligonucleotides exhibited reasonable linearity in 
each tissue homogenate, including the liver, spleen and tumor, but the attenuation coefficient 
of these tissues (the slopes in Figure 2.5) were dramatically different. While quantitative 
comparison in a tissue-specific manner is valid (e.g. liver vs. liver, tumor vs. tumor), it is not 
appropriate to measure the accumulated amount of the dose by comparing fluorescence 
intensity between different tissues.  
 
Figure 2.2 Biodistribution of LCP NPs in tumor-bearing mice.  
Signals were detected by (A) 3H, (B) 111Indium, and (C) fluorescence (Texas Red) signals.  
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Figure 2.3 Measured fluorescence intensity of Texas Red oligonucleotides.  
(A) Texas Red signal in whole organs; (B) Texas Red signal in tissue homogenate; (C) Texas 
Red signal in non-perfused and perfused liver. (Excitation/emission wavelengths: 550/600 
nm).   
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Figure 2.4 Measured fluorescence intensity of Cy5.5 in tissue homogenate.   
(Excitation/emission wavelengths: 650/700 nm) 
 
 
 
Figure 2.5 Standard curve generated by quantifying the intensities of known 
concentrations of oligonucleotides.  
(Excitation/emission wavelengths: 550/600 nm) 
2.4 DISCUSSION  
Fluorescence labeling of macromolecules has played a major role in biomedical 
research. It is desirable because of its high sensitivity, excellent spatial and temporal 
resolutions, and the capability for multimodality imaging. It extends our ability to track a 
particular molecular, cellular, or even physiological event using noninvasive visualization 
and measurement within the in vivo context. In spite of the many advantages offered by 
fluorescence imaging, the technique also presents serious challenges. Some issues regarding 
the use of fluorescence imaging in different tissues include auto fluorescence, light 
 35 
absorption, and light scattering. NIR dyes generate less background fluorescence, since auto 
fluorescence in tissues is mostly excited by near ultraviolet and blue light and emits in the 
yellow range [105]. Moreover, it has been demonstrated that use of red and NIR probes 
increases the depth of penetration in mammalian tissues by several orders of magnitude by 
avoiding the major absorption regions of hemoglobin. However, it is note-worthy that 
hemoglobin exhibits a broad absorption band. Even though the absorption of hemoglobin is 
much less intense in the NIR region, its contribution (in particular, by oxyhemoglobin) to the 
total light attenuation is certainly not negligible for quantitative purposes. Scattering has a 
weak dependence on wavelength. It arises due to a different relative refractive index at the 
boundaries between two different structures, such as the extracellular ﬂuid and the cell 
membrane. Tissues vary greatly in size, component and microstructure; they are optically 
inhomogeneous. Given the larger size and increased hemoglobin content in the liver and the 
spleen, it is expected that the light signal would be greatly reduced. These  differences  may  
also be  attributed  to  the  light absorption  by  other  tissue  constituents  and  to  light 
scattering by lipid membranes and cell fragments. When using fluorescence intensity 
in optically heterogenous samples for quantitative purposes, careful method development and 
validation should be performed.  
In conclusion, although fluorescence imaging confers certain advantages for 
convenient biodistribution studies, the quantitative data from whole organs is dramatically 
affected by the scattering and the absorption properties of the organ. The fluorescence 
intensity detected by fluorescence imaging is not necessarily proportional to the number of 
molecules present. Fluorescence imaging is very practical and informative in initial 
experiments to demonstrate the whole-body distribution, unfortunately it yields only 
qualitative and semi-quantitative images due to artifacts from tissue heterogeneities. To study 
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the biodistribution of macromolecules quantitatively, methods such as radiotracing or mass 
spectrometry should be considered. Thus, in Chapter 4 and Chapter 5, the PK and 
biodistribution of LCP NPs were measured using nanoparticles containing 3H labeled 
oligonucleotide. 
 
 CHAPTER 3 
CHARACTERIZATION OF LCP NP FORMULATION 
 
In the present study, the LCP NP formulation (size around 30 nm) was used for two 
reasons. First, its unique core-membrane structure allows us to readily modify the surface with 
different lipids and various amounts of PEGylation (Figure 3.1). Second, LCP NPs can be easily 
purified due to the density difference between the particle and the extra excipient, which permits 
accurate surface characterizations (Figure 3.2). In this chapter, we demonstrate that LCP NPs 
were structured around a lipid bilayer-core and had a size of approximately 30nm. 
Fluorescence quantification estimated that up to 20% (molar percent of outer leaflet lipids) 
PEG could be grafted on the surface of LCP NPs. The presence of PEG on the surface of NPs 
can be characterized using X-ray photoelectron spectroscopy (XPS); a substantial increase in 
the C-O peak in high resolution C1s scans is an indication of PEG, the intensity of the 
increase is directly proportional to the PEG concentration on the surface. SANS 
measurements indicated that at the concentration of 20% at 40 °C, the surface PEG existed in 
a collapsed and entangled manner, instead of adopting the widely speculated, well-extended 
brush conformation. 
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3.1 INTRODUCTION 
To date, the characterization of NPs in terms of PEG density is only studied casually 
with many reports simply using an assumption of complete insertion of the input PEG 
molecules. To measure the PEG concentration on the surface of NPs accurately, it is 
necessary remove the unincorporated PEG molecules by filtration or centrifugation based on 
the difference in size or density. The LCP nanoparticles prepared by the method described in 
2.2 contain extra lipids (e.g. DOTAP or DOPC, Cholesterol and DSPE–PEG2000). To 
determine the accurate concentration of DSPE–PEG2000 on the surface of LCP NPs, sucrose 
gradient centrifugation was used to separate LCP NPs with extra lipids. Sucrose gradient 
centrifugation is commonly used in cell biology to separate the cellular organelles or 
macromolecules based on their density. The technique involves density gradients prepared by 
altering the sucrose concentration such that the top of the tube contains liquids of the lowest 
density and the bottom contains those with the greatest. In the presence of centrifugal force, 
dispersed particles migrate through the gradient until they reach a zone of density that is 
equal to their own. LCP NPs containing a calcium phosphate core are heavier than particles 
that only consist of lipids. Sucrose gradients were prepared by superimposing equal volumes 
of sucrose solutions layer by layer at decreasing concentrations. The LCP NPs containing 
dense CaP cores banded tightly at a certain position of sucrose solution, while the 
unassociated lipid was present as a smear at the top, as shown in Figure 3.2. 
While many of the PEG molecules are associated with the particles, they are not 
necessarily presented on the surface. Thus, the fluorescent labeling may overestimate the 
loading level, especially when large excesses of PEG are used in the preparation process. The 
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difference in zeta-potential of the NPs with and without PEG is an indication that PEG has 
coated the surface. We also performed XPS high-resolution carbon 1s scans. XPS is a very 
powerful surface analytical tool which allows characteristic elemental detection, chemical 
state identification, and quantification. XPS survey scans are known to be very effective in 
characterizing the PEG chains that have been grafted onto various solid matrices such as 
silicon and polystyrene. High resolution C1s scans provide more in-depth information from 
the characteristic C-O peak, with its intensity directly proportional to the PEG concentration 
on the surface. 
To investigate the conformation of PEG on surfaces of LCP NPs, we employed 
SANS in situ in water. SANS has emerged as a powerful, noninvasive technique used to 
characterize the structures of materials on solid and liquid surfaces and interfaces. 
Importantly, due to their low energies, cold neutrons do not bring any damage on sometimes 
fragile polymeric samples. SANS is also a bulk probe giving rise to the average polymer 
conformation over the entire sample. The water fraction inside the polymer layer can also be 
estimated. Detailed information of SANS is provided in APPENDIX A. 
                  
Figure 3.1  Proposed lipid bilayer-core structure of LCP NPs. 
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Figure 3.2  Schematic illustration of sucrose gradient centrifugation for purification. 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
22-mer oligonucleotides (sense sequence, 5’-CAAGGGACTGGAAGGCTGGG-3’,) 
labeled with Texas Red or Cy5.5 Dye (excitation/emission wavelengths of 550/600 nm and 
650/700nm, respectively), were purchased from Sigma, Inc. Both Texas Red and 3H-labeled 
oligonucleotides were used to mimic siRNA. Dioleoylphosphatidylcholine (DOPC), 
dioleoylphosphatydic acid (DOPA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[poly(ethylene glycol)2000] (DSPE-PEG2000), Rhodamine-dioleoyl-
phosphatidylethanolamine (Rhodamine-DOPE) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[poly(ethylene glycol)2000-N'-carboxyfluorescein]  (DSPE-PEG-
CF) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL).  
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3.2.2 Experimental animals 
All work performed on animals was in accordance with and approved by the 
University of North Carolina Institutional Animal Care and Use Committee. 
Pharmacokinetics and biodistribution studies of LCP NPs were performed in normal athymic 
nude (nu/nu) mice and mice carrying H460 human lung cancer xenografts. Tumors were 
allowed to grow to a size of around 0.2cm3 before injections. 
3.2.3 NP preparations 
NPs were prepared using the method described in Chapter 2. Two mg/mL Texas Red 
or 3H-labeled oligonucleotides in 8 mL cyclohexane oil phase (71% cyclohexane with 29% 
Igepal CO-520 as surfactant), and 2) 100 μL of 100 mM pH 9.0 Na2HPO4 also in 8 mL 
cyclohexane oil phase plus 320 μL of 20 mM DOPA as the inner leaflet lipid. After mixing 
the above two solutions for 45 min, 30 mL of absolute ethanol was added to the micro-
emulsion and the mixture was centrifuged at 12,500 g for 15 min to precipitate the CaP core. 
After being washed with ethanol 2–3 times, the pellets were dispersed in 500 μL chloroform 
and stored in a glass vial for further modification. The outer leaflet lipid coating was created 
by mixing 200 μL of 20 mM cholesterol, 200 μL of 20 mM DOPC, and 100 μL of 20 mM of 
DSPE-PEG2000 with the core. After removal of the chloroform, the core was first suspended 
in a small volume of ethanol and then dispersed in 5 % Dextrose. 
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3.2.4 Sucrose gradient centrifugation  
The discontinuous sucrose gradient was created with 0.9 mL each of 60% sucrose, 
40% sucrose, 20% sucrose and deionized water layered consecutively from bottom to top in 
4 ml ultracentrifuge tubes. The mixture containing LCP NPs and extra lipids was applied 
between 10% sucrose and water. The gradients were centrifuged using a Beckman Coulter 
SW 60Ti rotor at 168,000g for 4 h at 20°C and then separated into aliquots removed from top 
to bottom. The fractions were then diluted with ethanol and lysis buffer (0.1% Triton-100 and 
HCl, pH=2.5) for further measurements.  For the SANS experiment, LCP NPs were purified 
using 2H2O and 2H-sucrose.  
3.2.5 Transmission electron microscopy 
The size and morphology of the condensed CaP core were determined by 
transmission electron microscope (TEM) with an acceleration voltage of 100 kV. To prepare 
the samples, CaP core suspended in CHCl3 (2 μL) were deposited onto a 200 mesh copper 
grid coated with carbon (Ted Pella, Inc., Redding, CA), followed by air drying at room 
temperature. Images were acquired using a JEOL 100CX II TEM. 
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3.2.6 Dynamic light scattering and Zeta potential  
The final products, LCP NPs with different lipids grafted to their surface, were 
diluted with water appropriately. Zeta potential and particle size of the LCP NPs were 
determined by using a Malvern ZetaSizer Nano series (Westborough, MA). 
3.2.7 Fluorescence-labeled lipids analysis 
To identify the composition of each faction, Rhodamine-DOPE, DSPE-PEG2000-CF 
and 3H labeled oligonucleotide were used to label the outer leaflet lipid, PEG2000-DSPE and 
CaP core, respectively. The LCP NPs were prepared and purified as described above. The 
fractions were analyzed using a fluorescence spectrometer and liquid scintillation counter.  
3.2.8 X-ray photoelectron spectroscopy study  
LCP NPs with varying PEG surface concentrations were prepared and purified as 
described above and the sucrose was removed. Concentrated LCP NPs were then placed onto 
a gold substrate, forming a thin, uniform layer. The samples were degassed under vacuum 
before introduction to the XPS stage. A Kratos Axis Ultra DLD X-ray Photoelectron 
Spectrometer (Kratos Analytical Ltd.) was used to make the XPS measurements, analyzing 
the elemental composition of the top 5nm of the sample surface. High-resolution scans of the 
carbon 1s photoelectron were used to obtain the intensity of the C-O carbon peak, which is 
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characteristic of a PEG chain. All scans of carbon 1s photoelectrons were peak-fitted using 
software provided with the instrument. 
3.2.9 Small angle neutron scattering study 
SANS data were collected on the EQ-SANS instrument of the Spallation Neutron 
Source of Oak Ridge National Laboratory [106].  A sample-to-detector distance of 4m was 
employed.  The instrument was operated in the 30 Hz, frame-skipping mode using a 
minimum wavelength (λ) of 2.5 Å to produce two bands of neutrons (2.5 Å < λ1 < 6.1 Å and 
9.4 Å < λ2 < 13.4 Å). This method provides an effective q-range of 0.005 Å-1 to 0.42 Å-1, 
 and θ is the scattering angle. The sample temperature was controlled by a water bath.  Data 
reduction, which was completed using the MANTID software package 
(http://www.mantidproject.org/), followed standard procedures to correct for incident neutron 
flux, detector sensitivity, wavelength-dependent transmission, dark current (electronic noise 
and cosmic radiation) and solvent scattering.  The reduced data were azimuthally averaged 
into I(q) vs. q. The instrument resolution at a given q-value in the final, reduced data was 
determined to be the weighted average of the instrument resolutions for the wavelengths 
contributing to that particular q-bin.  The data from the two different wavelength bands were 
merged into a single profile using the method implemented in MANTID. A polydispersed 
core-with-3-shell spherical model developed at the National Institute of Standards and 
Technology (NIST) Center for Neutron Research (NCNR) using IGOR Pro software  was 
used to fit the SANS data [64, 107]. 
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3.2.10 Statistical analysis 
All statistical analyses were performed by a two-tailed student t-test. Data were 
considered statistically significant when P value was less than 0.05. 
3.3 RESULTS 
3.3.1 Size, morphology and surface charge of LCP NPs 
Characteristics of purified LCP NPs are summarized in Table 3.1. All the NPs were 
PEGylated at an optimal density of 20% molar ratio of the total outer leaflet lipid. Both LCP-
DOTAP and LCP-DOPC NPs had a hydrodynamic diameter of about 30 nm. When the 
particles were formulated with DOPC as the outer leaflet lipid, the zeta potential was 
approximately -10 mV. In contrast, when DOTAP was employed, the surface potential 
became around 15 mV. The slightly positive surface charge might be an indication of PEG 
modification on the NPs, in contrast to that of pure DOTAP liposomes (~70 mV). At a 
concentration as high as 20%, the PEG coating is supposed to achieve steric shielding of the 
NPs’ surface and thus create the “stealth” property [46, 61]. 
The images of the CaP cores were taken without staining, allowing the observation of 
the size of the cores, which was approximately 10–15 nm. The TEM images indicated that 
the outer layers of the particles also had high electron intensity, but the inner layers had a 
lower intensity, suggesting that the CaP cores were of a hollow structure (Figure 3.3).  
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Table 3.1 A summary of characteristics of LCP NPs. 
 
 
 
        
Figure 3.3 TEM image of CaP cores. 
Scale bar indicates 10 μm. 
3.3.2 Surface coverage of PEG 
As discussed above, the LCP NPs prepared using the method described in 2.2 contain 
extra lipids. To determine the accurate concentration of DSPE–PEG2000 on the surface of 
LCP nanoparticles, sucrose gradient centrifugation was used to separate LCP NPs from the 
extra lipids. The LCP NPs containing dense CaP cores banded tightly at the interface 
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between the layer of 20% and 40% sucrose, while the unassociated lipids were present as a 
smear from the top of the gradient to the interface between 20% and water (Figure 3.2). We 
found that the isolated purified LCP NPs contain around 90% tritium and calcium (by 
inductively coupled plasma mass spectrometry, ICP-MS).  Rhodamine-DOPE, DSPE-
PEG2000-CF and trace amounts of tritium were detected in the fractions of lower sucrose 
concentrations, suggesting that extra lipids could be separated from the dense nanoparticles 
using this method.  
Rhodamine-DOPE and DSPE-PEG2000-CF were used to measure the molar ratio of 
DSPE-PEG2000-CF in the total outer leaflet lipid. Quantification of DSPE-PEG-CF on 
purified LCP NPs is summarized in Figure 3.4. The addition of a PEG solution during the 
preparation process produced nanoparticles with approximately the same concentration of 
PEG as the addition. For example, using 10% PEG-phospholipid solution resulted in purified 
NPs with 10% PEG-phospholipid. A saturation of PEG incorporation was observed at 20% 
molar ratio of the total outer leaflet lipid. Furthermore, the charge of the substrate lipid did 
not influence the amount of PEG coating. No significant difference was found between LCP 
NPs coated with positively charged lipid DOTAP and neutral lipid DOPC. 
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Figure 3.2 Quantitative analysis of DSPE-PEG-CF on purified LCP NPs. 
 
XPS high-resolution carbon 1s scans were used to determine the presence of the PEG 
on the surface. LCP NPs without PEGylation (0% PEG) were used as a control. Figure 3.5 
shows the high-resolution carbon 1s scan for surface of LCP NPs with 20%, 10% and 0%. 
The peaks were resolved into various components, corresponding to C-C and C-H bonds at 
285.0 eV, C-O bond at 286.5 eV, and to C=O bond at higher energy level. The presence of 
PEG on the nanoparticle surface can be characterized by a substantial increase in the C-O 
peak in high resolution C1s scans with its intensity directly proportional to the PEG 
concentration on the surface, thus enabling the quantitative determination of PEG on the 
surface [108]. The scans clearly show the growing intensity of the C-O peak at 286.5 eV as 
the PEG concentration increases, indicating the increasing grafting density of PEG. It is 
difficult to calculate the exact amount of the PEG due to the presence of C-O in the lipid 
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layer. However, most of the C-O signal comes from the PEG coating and  the  trend  of  these  
observations confirms  the  presence  of  the  PEGylation on the surface of LCP NPs.   
 
 
 
 
Figure 3.3 High resolution carbon 1s scans of LCP NPs with different amount of 
PEGylation. 
Scale bar indicates 10 μm. 
 
3.3.3 Conformation of surface-grafted PEG 
SANS measurements on the samples at different temperatures (10 and 40 oC) were 
conducted in order to investigate the PEG conformation on the surface of LCP NPs. It has 
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been reported that the elevation of temperature leads to a decrease in solubility of PEG in 
water, resulting in a transition of polymers with PEG side chains in an extended state into 
PEG chains with a collapsed state [109]. Therefore, the SANS curves of the LCP NPs are 
expected to differ at different temperatures, as shown in Figure 3.6. The varying size 
distribution of LCP particle size (judged by TEM micrograph in Figure 3.3) creates 
difficultly when fitting the whole q range. Therefore, we focused on the largest difference 
between the SANS data occurring at 10 and 40 oC (q > 0.02 Å-1). Presumably the difference 
results from the temperature response of the PEGylated lipids on the surface of the LCP. The 
intensity within a q range of 0.23 and 0.5 Å-1 increases when the sample is at 10 oC due to 
the extension of PEG chains on the LCP surface.  
Based on the TEM images (Figure 3.3), LCP has a hollow core (possibly water) and 
a shell (possibly CaP). From the scheme of microemulsion, a bilayer with DSPE-PEG at the 
outer leaflet should be expected. However, this bilayer was not observed in TEM, perhaps 
due to a low contrast. Following these observations, the polydispersed core-with-3-shell 
spherical model is used to fit the SANS data. The three shells represent the CaP, lipid and 
hydrated PEG regions, moving from the inside to the outside, respectively. Since the amount 
of sucrose and the concentration of LCP cannot be precisely determined during the sample 
preparation, obtaining absolute scattering intensity of the system provides no advantages. In 
order to minimize the number of variables and avoid a local minimum, most of the fitting 
parameters are constrained according to the physical properties or information from the TEM 
results. The initial values and the allowed varying range with respect to scattering length 
densities (SLDs) of the solvent (solv), the hydrated PEG layer (PEG), the lipid bilayer (lip) 
and CaP (CaP) and hollow core (core) were set to be (6x10-6 ± 10%), (3x10-6 ± 100%),  4x10-
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7 (fixed), (3.9x10-6 ± 10%)  and (6x10-6 ± 10%) Å-2, respectively. The average radius of the 
hollow core, Rcore and thickness of CaP, tCaP were initially set to be 35 and 30 Å, 
respectively, based on the TEM data, while the lipid bilayer thickness (tlip) was constrained 
in the normal range between 20 and 40 Å. The final, best-fitting parameters of the model for 
the 10 oC data were solv = 5.5 x 10-6 Å-2, PEG = 1.85 x 10-6 Å-2, lip = 4 x 10-7 Å-2, CaP = 
4.5 x 10-6 Å-2, core = 6.3 x 10-6 Å-2, tcore = 35.7 Å, tCaP = 31.1 Å, tlip = 25 Å and thickness 
of hydrated PEG (tPEG) = 8.3 Å.  
The same parameters were used to fit the 40 oC data, except for the values of PEG 
and tPEG, which were allowed to vary freely. As a result, both models agree with the data 
reasonably well (Figure 3.6). The two facts that the hydrated PEG layer decreased from 8.3 
Å to nearly 3.7 Å and that the bilayer becomes slightly thicker (from 25 Å to 21 Å) with an 
increase in temperature are consistent with the collapsed state of PEG chains. Based on the 
scattering length densities (SLDs) of the hydrated PEG layer and solvent at 10 oC, the 
volume fraction of water in the PEG layer is estimated to be ~20%. Since the molecular 
weight (MW) of PEG is ~2000 g/mol, the radius of gyration (RG) is estimated to be 18 Å 
[110], resulting in an overlapping concentration (~ ) of 0.174 g/mL, which is less than 
¼ of the volume fraction of PEG obtained from the SANS data. These results suggest that the 
PEG layer should exist in a heavily overlapping regime (Table 3.2). It should be noted that 
the best-fit result seems to underestimate the thickness of the hydrated PEG layer on the LCP 
surface. The discrepancy is possibly attributed to the fact that the model assumes a constant 
SLD to describe the PEG layer, although, realistically, it may have a diffuse density profile.    
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Figure 3.6 SANS data of the LCP NPs at 10 oC (circles) and 40 oC (triangles). 
The solid lines are best fits to both data sets. 
 
 
 
Table 3.2 The thickness of the lipid and PEG layers based on a polydispersed core-with-
3-shell spherical model. 
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3.4 DISCUSSION 
In this chapter, we demonstrated the ability to formulate a core-membrane structured 
nanoparticle with full coverage of PEG on the surface.  On the basis of fluorescence-labeled 
PEG analysis, XPS carbon 1s scans, and SANS modeling, a densely grafted, inter- and intra- 
molecular entangled PEG layer was observed.  
Our group [79], and others in the early 1990s [111], demonstrated RES avoidance and 
long circulation half-life achieved by surface incorporation of PEG in liposomes.  This 
method employs PEG-phospholipids which could by anchored on the lipid membrane by 
hydrophobic interactions. Due to the amphiphilic nature of the PEG-phospholipids, the 
degree of surface PEGylation is quite limited; usually less than 5 % if the lipid membrane 
integrity is to be preserved [61].  However, high density of PEG is necessary to achieve steric 
shielding of the nanoparticles’ surface and thus create the “stealth” property. The unique 
core-membrane structure of LCP NPs presents an efficient and robust platform for high 
density PEGylation. In this formulation, the inner leaflet lipid (DOPA) is known to strongly 
interact with cations (Ca) in the core and is therefore supported and stabilized by the solid 
and positively charged core. Owing to this substrate-membrane interaction, the supported 
bilayer has greater stability than unsupported liposomal bilayers [112, 113] and permits a 
high amount of incorporated DSPE-PEG2000, a detergent-like surfactant. This platform 
provides an opportunity to modify the formulation with a high-density PEG coating and 
explore the impact of a PEG coating on the in vivo behavior of nanoparticle formulation.  
By labeling DSPE-PEG2000 with a green fluorescent dye, it was determined that LCP 
nanoparticles could tolerate as much as 20% PEG-phospholipids. XPS analysis verified that 
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the surface of LCP NPs was covered by a substantial amount of PEG. SANS further 
estimated that these PEG chains should exist in a heavily overlapping regime, forming a 
collapsed and entangled polymer layer on the surface. In all cases, there was good agreement 
between the measurements obtained from each method. Although it is widely accepted that, 
theoretically, a very high grafting density usually translates to a PEG brush, our findings 
suggest that a compact polymer layer is present. To the best of our knowledge, there are no 
reports on direct evidence regarding lipid-based NP surfaces modified with a PEG-based 
brush. Due to the large excluded volume and large number of hydrogen bonds of PEG 
chains, the energy penalty of the polymer chains adopting an extended conformation would 
be extremely high. Therefore, a surface in which PEG chains exist as a tangled mass is 
energetically favored. 
 
 
 
 CHAPTER 4 
PHARMACOKINETICS AND BIODISTRIBUTION OF LCP NP 
 
We have developed an LCP NP formulation with a well-defined lipid bilayer-core 
structure to examine the effect of PEG density and different surface lipids on the in vivo fate 
of NPs. It has been demonstrated that 20% (molar percent of outer leaflet lipids) could be 
grafted on the surface of LCP NPs. The surface PEG existed in a collapsed and entangled 
manner. The PK and biodistribution studies of LCP NPs formulated with DOPC and DOTAP 
as the surface lipids were conducted in normal and tumor-bearing mice. The densely 
PEGylated LCP displayed a biphasic clearance profile. NPs were taken up by the liver, 
spleen and tumor after their intravenous injection. A substantial amount of the injected dose 
was observed in the liver. Within the liver, confocal microscopy revealed that LCP NPs were 
localized in hepatocytes; Kupffer cell uptake was absent. Uptake of LCP by Kupffer cells 
and splenic macrophages appeared when the surface PEG density decreased to below 15%. 
LCP NPs with DOTAP exhibited higher accumulation in the liver than LCP NPs with 
DOPC. 
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4.1 INTRODUCTION 
To be useful in vivo, NPs must avoid opsonization and subsequent recognition by 
macrophages. This can be accomplished through PEGylation [114]. Surface-modification of 
NPs with PEG has been widely used to prolong the circulation time and improve in vivo 
performance of various nanoscaled carriers. The success of PEGylation critically depends on 
the steric stabilization conferred by PEG chains on the surface of the NPs. Stabilization is 
achieved through the highly hydrophilic and flexible nature of PEG chains, which provide 
repulsive interactions with biological components in vivo. The ways in which grafted PEG 
forms a well hydrated barrier layer on the surface, sterically hindering protein adsorption, 
were thoroughly discussed in Chapter 1.  
We have demonstrated that the LCP NP formulation can effectively deliver siRNA 
[99, 103] to both solid and metastatic tumors. In Chapter 3, we showed that the surface of 
NPs containing a supported lipid bilayer could be modified with a high amount of PEG (20 
mol%). A complete shielding of the NP surface was found with a neutral or slightly positive 
zeta potential. The data suggest that the NPs with full surface protection may show improved 
EPR effect, improving solid tumor delivery.  
Here, we investigated the in vivo PK and biodistribution of the LCP NPs in normal 
and tumor bearing mice. This formulation was chosen for two reasons; first, the unique 
membrane-core structure allows for modification of the surface with various amounts of 
PEGylation. Second, LCP NPs can be purified based on the density difference between the 
particle and the extra excipient, which permits accurate surface characterizations of 
PEGylation. We have studied the physical conformation of the PEG chains at high graft 
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density and correlated with the PK and tissue distribution of the modified LCP NPs after 
intravenous administration. The results of the experiment have revealed some surprising 
conclusions that are not predicted by existing theories. We believe these findings will benefit 
the rational design and application of PEG and other hydrophilic polymers for the 
development of effective drug carrier systems.  
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
22-mer oligonucleotides (sense sequence, 5’-CAAGGGACTGGAAGGCTGGG-3’,) 
labeled with Texas Red or Cy5.5 Dye (excitation/emission wavelengths of 550/600 nm and 
650/700nm, respectively), were purchased from Sigma, Inc. Both Texas Red and 3H-labeled 
oligonucleotides were used to mimic siRNA. Dioleoylphosphatidylcholine (DOPC), 
dioleoylphosphatydic acid (DOPA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[poly(ethylene glycol)2000] (DSPE-PEG2000) were purchased from Avanti Polar Lipids, Inc. 
(Alabaster, AL). NCI-H460 human lung cancer cells were obtained from American Type 
Culture Collection.  
4.2.2 Experimental animals 
All work performed on animals was in accordance with and approved by the 
University of North Carolina Institutional Animal Care and Use Committee. 
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Pharmacokinetics and biodistribution studies of LCP NPs were performed in normal athymic 
nude (nu/nu) mice and mice carrying H460 human lung cancer xenografts. 
4.2.3 NPs preparation  
LCP NPs were prepared as previously described in the Chapter 2.  The formulations 
were used without further purification. 
4.2.4 PK study 
PK studies of LCP NPs were performed in normal nude mice and mice carrying H460 
human lung cancer xenografts. Tumors were allowed to grow to a size of around 0.2 cm3 
before injections. Animals were intravenously injected with in LCP NPs containing 3H 
labeled oligonucleotide at a dose of 0.25 mg/kg. At selected time points, mice were sacrificed 
and blood was collected through parallel sampling. The amount of 3H labeled oligonucleotide 
in the blood was quantified using liquid scintillation counting. Under the assumption that the 
total blood volume in the mouse is 7% of its body weight, NP concentrations in the blood 
were calculated. 
4.2.5 Tissue distribution study 
Tissue distribution studies of LCP NPs were performed in normal athymic nude mice 
and mice carrying H460 human lung cancer xenografts. Tumors were allowed to grow to a 
size of around 0.2 cm3 before injections. Animals were intravenously injected with LCP NPs 
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containing 3H labeled oligonucleotide at a dose of 0.25 mg/kg. At selected time points, mice 
were sacrificed and the heart, liver, spleen, lungs, kidneys and tumors were collected. The 
tissues were dissolved in NCS Tissue Solubilizer (GE Healthcare, Life Sciences) and the 
amount of 3H labeled oligonucleotide in the different tissues was quantified using liquid 
scintillation counting.  
4.2.6 Cell-type specific localization by confocal microscopy  
Mice were intravenously injected with Texas Red-labeled oligonucleotides contained 
in different LCP NP formulation four hours before sacrifice and tissue collection. Tissue 
blocks were immediately frozen in OCT (Tissue-Tek, Dublin, OH) on dry ice, allowing the 
generation of ten-µm-thick cryosections. The tissue sections were then mounted on 
Superfrost Plus slides (Fisher Scientific Co., Houston, TX). After a brief rinsing with PBS to 
remove any surface embedding medium,  we completed fixation of the particles with acetone 
at -20 °C. Then, tissue sections were stained with Alexa Fluor 488 phalloidin (Life 
Technologies) and mounted in a medium containing DAPI (Vector Lab.). Images were 
captured using an Olympus FV1000 MPE confocal microscope under three channels: DAPI 
for nuclei, Alexa Fluor 488 for phalloidin, and Texas Red for oligonucleotide. 
4.2.7 Statistical analysis 
Data are presented as the mean ± SD. 
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4.3 RESULTS 
4.3.1 Blood Clearance 
The blood clearance kinetics 4 h after injection are shown in Figure 4.1. No 
significant differences in the PK profiles were observed between the tumor free and the 
tumor-bearing mice treated with LCP NPs containing 3H-labeled oligonucleotide. NPs in 
both types of mice showed a rapid distribution phase, in which serum concentrations dropped 
dramatically within the first 30 min. After that, concentrations remained steady for at least 
3.5 h.  A standard bi-exponential clearance model was used to describe the blood 
concentrations of NPs using WinNonlin Version 5.2 (Pharsight, St. Louis, MO). Between 
fifty and sixty percent of the injected dose (ID) was cleared with a half-life of around 15 min 
in the distribution phase; the rest was cleared with a longer half-life of 6 h in the clearance 
phase. 
 
 62 
 
 
Figure 4.1. Pharmacokinetics of LCP NPs in normal and tumor-bearing mice.  
Data are plotted as % injected dose vs time (N=4). The outer leaflet lipid is DOPC. PEG 
concentration is 20% (molar percent of outer leaflet lipids).  
 
4.3.2 Kinetics of tissue distribution 
To investigate the kinetics of the LCP NPs’ distribution into major organs, we 
performed the biodistribution study during the 4 h after injection. The tumor-free and tumor-
bearing mice demonstrate nearly identical distribution kinetics in major organs (Figure 4.2A 
and B). A rapid increase in the 3H signal in the liver and spleen (usually considered to be 
RES organs) coincided with the initial distribution phase in the plasma. The 3H signal 
reaches a plateau about 1 h after injection. This lack of accumulation may indicate that NPs 
extravasate from liver sinusoids into the space of Disse, but are not taken up to a significant 
degree by resident macrophages or hepatocytes. At 4 h after injection, the liver and spleen 
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showed significant accumulation of the 3H signal (~25% ID and 15% ID, respectively), both 
in excess of that in the tumor (<5% ID). No significant signal accumulated in the kidney, 
indicating that the particles do not disintegrate or release the encapsulated cargo in 
circulation. Despite complete NP PEGylation, substantial amount of accumulation still 
occurred in the RES organs (liver and spleen). A fairly small percentage of the dose reaches 
the tumor site. The results also show that blood clearance and tissue distribution kinetics are 
approximately equal in both tumor-free and tumor-bearing mice.  
 
Figure 4.2 Tissue distribution of LCP NPs as a function of time after administration. 
(A: normal mice; B: tumor-bearing mice. N=4)  Data are plotted as % injected dose vs time.  
The outer leaflet lipid is DOPC. PEG concentration is 20% (molar percent of outer leaflet 
lipids).  
 
4.3.3 Cell-type specific localization in liver and spleen  
PEG dependence of hepatocytes delivery was investigated using LCP NPs with 
various amounts of PEG coating. Confocal microscopy of liver sections harvested from mice 
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4 h after injection of nanoparticles containing Texas Red-labeled oligonucleotide are shown 
in Figure 6. Tissues were stained with phalloidin to visualize cell membranes of all cell 
types. Significantly, preferential accumulation of the Texas Red-labeled oligonucleotide in 
hepatocytes (also called liver parenchymal cells, which contain large DAPI-stained blue 
nuclei) was observed in mice treated with LCP NPs containing a high density of PEG 
(Figure 4.3A5-6). Distribution was generally homogenous throughout the different zones 
and the liver acinus. Hepatocyte uptake was markedly reduced by decreasing the amount of 
PEG on the surface of nanoparticles. LCP NPs with a lower density of or completely without 
PEG rarely entered hepatocytes (Figure 4.3A2 and 3). Instead, they experienced phagocytic 
uptake by Kupffer cells and resided in hepatic sinusoids (a region between hepatocytes as 
indicated by the arrow, Figure 4.3). Inspection of the spleen revealed that substantial Texas 
Red signals were found localized in the red pulp region in mice treated with LCP NPs 
containing a lower density of PEG. A very limited amount of signal in the spleen was 
observed in tissues injected with LCP NPs coated with a high PEG density (Figure 4.3B). 
This observation is consistent with the significant uptake of low and high-PEG LCP NPs by 
Kupffer cells and hepatocytes, respectively, in the liver. These results are evidence that 
delivery to the hepatocytes is enabled by grafting a dense PEG layer on the surface of LCP 
NPs. They also suggest that PEG concentration determines cell-type specific localization at 
the tissue level. We conclude that LCP NPs with a high PEG density (~20%) completely 
evaded RES and accumulated primarily in the hepatocytes. 
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Figure 4.3 Cell-type specific localization of LCP NPs in liver (A) and Spleen (B). 
DAPI for nuclei, Alexa 488 for phalloidin, and Texas Red for oligonucleotides. Percentages 
indicate amount of PEG-DSPE2000 incorporated in the outer leaflet of the wrapping lipid 
bilayer of LCP NPs. Arrows indicate representative Kupffer cell uptake. 
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4.4 DISCUSSION 
Despite complete nanoparticle PEGylation, significant accumulation still occurred in 
the RES organs (liver and spleen); only a minor amount of the dose accumulated in the 
tumor. The results also show that blood clearance and tissue distribution kinetics are 
approximately equal in both tumor-free and tumor-bearing mice. This is likely a consequence 
of the small size of the LCP nanoparticles (~30nm). Extravasation in the liver is plausible 
because the presence of fenestrae in liver sinusoids, which measure 100 nm in diameter in 
mice [14]. This condition can be described by a two-compartment model with, as shown in 
Figure 4.4. Nanoparticle elimination from the central compartment occurred due to RES 
uptake and distribution to the peripheral compartment (tissues with discontinuous 
endotheliums), where Xb, XT  and XL are the amount of NPs in blood, tumor and liver, 
respectively. K10 is the elimination rate constant from the central compartment by RES 
uptake and K12, 21, 13, 31 are the intercompartmental transfer rate constants. VT and VL are the 
volume of distribution of tumor and liver, respectively. For simplicity, we are assuming that 
these processes are all occur in a first-order fashion. The tumor tissue retains NPs due to a 
lack of lymphatic drainage; consequently, K21 would be negligible compared with other 
intercompartmental transfer. K10 depends on the properties of the NPs, such as size and 
surface chemistry, which was discussed in Chapter 1.  
In this study, PEG density and the EPR effect are the determinants of K10 and K12, 
respectively. The PK and biodistribution results suggest that the distribution of small, long-
circulating NPs to tissues with discontinuous endotheliums could become competing kinetic 
processes (i.e. K12 and K13), dependent on the properties of nanoparticles, vasculature 
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permeability, and blood flow. Given the limited blood flow through the tumor and its 
relatively small volume, a highly perfused organ with a discontinuous endothelium, such as 
the liver, can easily outpace the tumor and thus become the major distribution site. 
The significant uptake by the hepatocytes is of great interest to formulation design in 
biomedical applications due to its importance in many infectious and metabolic disorders. On 
the other hand, it highlights a potentially important complication in the development of 
nanoparticles regarding imaging and therapeutic applications in oncology. Recently, there is 
increasing evidence that small nanoparticles in the size range of 10-30 nm can more 
effectively penetrate the physiological barriers imposed by tumor vasculature and the 
interstitial matrix than larger particles [88, 115]. Similarly, avoiding rapid distribution to the 
liver will be another critical design criterion for future nanoparticle systems targeting tumor 
sites. 
 
 
Figure 4.4 Proposed two-compartment PK model in the tumor-bearing mice. 
X0 = injected dose; Xb XT XL=concentration in blood, tumor and liver; 
V =volume of distribution, k10= clearance coefficient; 
K12, 21, 13, 31=transportation coefficient. 
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In summary, we have shown that a high density of PEG coating with heavily 
overlapped and collapsed regime was placed on the surface of LCP NPs. This PEG coating 
enables delivery to the hepatocytes and avoidance of RES uptake, although whether the 
hepatocyte uptake is specific to lipid-based nanoparticles is still unknown. This study 
established a relationship between the physicochemical properties of nanoparticles and their 
in vivo pharmacokinetics and biodistribution profile, which may provide important 
information for a rational formulation development approach.  
  
CHAPTER 5 
PROTEIN ADSORPTION AND ITS IMPACT ON IN VIVO BEHAVIOR 
 
PK and biodistribution of nanoparticulate carriers are controlled by a complex array 
of interrelated physicochemical and biological factors. Surface chemistry of NPs has been 
identified as one of the key determinants of these characteristics. LCP NPs are an effective 
drug delivery system to both solid and metastatic tumors. The well-defined lipid bilayer-core 
structure of the LCP NPs allows us to examine the effect of different surface lipids on the in 
vivo fate of NPs. The PK and biodistribution studies of LCP NPs formulated with DOPC and 
DOTAP were conducted in normal and tumor-bearing mice. NPs were taken up by the liver, 
spleen and tumor after their intravenous injection. LCP NPs with DOTAP exhibited higher 
accumulation in the liver than LCP NPs with DOPC. Analysis of NP-bound proteins revealed 
that apoE might serve as an endogenous targeting ligand for LCP-DOTAP NPs, but not LCP-
DOTAP NPs. The enhanced liver accumulation with LCP-DOTAP NPs was reduced in apoE 
deficient mice. In all, characteristics of the surface lipids played important roles in 
influencing PK and biodistribution of LCP NPs. Understanding the NPs-protein interaction is 
necessary for rational engineering of NPs with favorable in vivo behavior.  
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5.1 INTRODUCTION 
In comparison to bulk biomaterials, NPs have an extremely high surface-to-volume 
ratio. Control of their surface properties is crucial to their in vivo performance. The surfaces 
of NPs are immediately covered by proteins after they have been injected into the blood. The 
absorption of proteins to such surfaces confers a new “biological identity” to NPs in the 
biological milieu, which is what cells, tissues and organs actually “see” when interacting 
with NPs [67]. This new “bio-nano interface,” created by covering NPs with a complex layer 
of protein “corona” determines the subsequent cellular/tissue responses and biological 
consequence [68, 69]. Surface characteristics such as charge, hydrophilicity and curvature 
dictate the extent and specificity of protein binding [67, 70]. Specific protein binding is one 
of the key elements that affect biodistribution of the NPs. Indeed, a detailed knowledge of 
NP-protein interaction is vital for the rational formulation design and optimization of 
nanoparticles.  
The aim of the present study was to identify the influence of surface lipid 
composition on the PK and biodistribution of LCP NPs. Moreover, we investigated the 
underlying mechanism in terms of the nature of the adsorbed proteins. The unique bilayer-
core structure of LCP NP formulation allows for readily modification of the surface with 
different lipid. Thus, this single tool may serve as a platform for the rational design and 
investigation of novel lipid-based drug carriers. The in vivo biodistribution and 
pharmacokinetics studies of LCP NPs modified with DOPC and DOTAP were conducted in 
normal and tumor-bearing mice. We then analyzed the composition of the protein corona 
which bound the NPs with difference surface chemistry, using one-dimensional sodium 
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dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and matrix-assisted, laser-
desorption ionization, time-of-ﬂight mass spectrometry (MALDI-TOF-MS). The results 
suggested that the enrichment of apolipoproteins on the surface of LCP-DOTAP NPs might 
be the explanation of its enhanced liver accumulation. This information is helpful in 
determining the advantages and disadvantages of the outcome for the various proteins and 
facilitating development of effective drug carriers. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials  
22-mer oligonucleotides (sense sequence, 5’-CAAGGGACTGGAAGGCTGGG-3’,) 
labeled with Texas Red or Cy5.5 Dye (excitation/emission wavelengths of 550/600 nm and 
650/700nm, respectively), were purchased from Sigma, Inc. Both Texas Red and 3H-labeled 
oligonucleotides were used to mimic siRNA. Dioleoylphosphatidylcholine (DOPC), 
dioleoylphosphatydic acid (DOPA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[poly(ethylene glycol)2000] (DSPE-PEG2000) were purchased from Avanti Polar Lipids, Inc. 
(Alabaster, AL). NCI-H460 human lung cancer cells were obtained from American Type 
Culture Collection.  
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5.2.2 Experimental animals    
All work performed on animals was in accordance with and approved by the 
University of North Carolina Institutional Animal Care and Use Committee. 
Pharmacokinetics and biodistribution studies of LCP NPs were performed in normal athymic 
nude (nu/nu) mice and mice carrying H460 human lung cancer xenografts. ApoE-deficient 
mice (ApoE-/-, stock #002052) and wild type C57BL/6 mice were obtained from Jackson 
Laboratories (Bar Harbor, ME).  
5.2.3 NPs  preparation 
NPs were prepared as previously described in Chapter 2.  The particles were purified 
using sucrose gradient centrifugation as described in the Chapter 2 to enable the completion 
of a protein adsorption assay. The formulation was used without further purification in all of 
the animal studies. 
5.2.4 PK study 
PK study of LCP-DOTAP was performed in normal mice and mice carrying H460 
human lung cancer xenografts. Tumors were allowed to grow to a size of around 0.2 cm3 
before injections. Animals were intravenously injected with in LCP NPs containing 3H 
labeled oligonucleotide at a dose of 0.25 mg/kg. At given time intervals, four animals were 
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sacrificed for blood collection. Radioactivity was measured using liquid scintillation 
counting.  
5.2.5 Tissue distribution 
Biodistribution studies of LCP NPs were performed in normal athymic nude (nu/nu) 
mice and mice carrying H460 human lung cancer xenografts. Tumors were allowed to grow 
to a size of around 0.2cm3 before injections. Animals were intravenously injected with in 
LCP NPs containing 3H labeled oligonucleotide at a dose of 0.25 mg/kg. Four hours after 
injection, animals were sacrificed for tissue collection. The tissue samples were processed as 
described in Chapter 4. Radioactivity was measured using liquid scintillation counting.  
5.2.6 Cell-type specific localization in liver 
Confocal microscopy imaging of the frozen section of liver was conducted as 
described in Chapter 4. 
5.2.7 Determination of the protein corona composition   
LCP NPs with different surface lipids and PEG densities were prepared and purified 
as described above. Samples were incubated at different serum concentrations (20% and 
80%). NPs were allowed to incubate with the serum solutions for 1.5 hours. After the 
incubation, the samples were centrifuged to pellet the particle-protein complexes, separating 
them from the supernatant. Afterwards, the pellets were washed three times with PBS and 
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then re-suspended in PBS in a protein loading buffer. Gel electrophoresis was performed at 
120V, 400mA for about 60 minutes. The gels were stained in coomassie blue staining and 
destained overnight in 50% methanol, 10% acetic acid [116, 117].  
After the separation of proteins by SDS-PAGE, bands were excised from the gel and 
digested with trypsin, and the resulting peptide mixtures were separated and analyzed by 
MALDI-TOF-MS (ABI 4800 MALDI TOF/TOF). Spectra were analyzed by MASCOT 
software to identify tryptic peptide sequences matched to the NCBI database 
(http://www.ncbi.nlm.nih.gov/).  
5.2.8 In vivo apoE dependency   
LCP NPs containing 3H labeled oligonucleotide were administered intravenously via 
the tail vein at a dose of 0.25 mg/kg into ApoE-deficient mice and wild type C57BL/6 mice, 
respectively. Four hours after injections, major organs were collected from animals and 
processed for radioactivity measurements.  
5.2.9 Statistical analysis 
Data are presented as the mean ± SD.  The statistical significance was determined by 
using the student’s t-test.  P values of <0.05 were considered significant. 
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5.3 RESULTS 
5.3.1 Blood Clearance 
As shown in Figure 5.1, no significant differences in the pharmacokinetic profiles 
were observed between the tumor free and the tumor-bearing mice treated with LCP NPs 
containing 3H-labeled oligonucleotide. The clearance of LCP NPs from the bloodstream was 
bi-exponential. NPs in both types of mice showed a rapid distribution phase, in which serum 
concentrations dropped to around 50% ID within the first 30 min. The rapid distribution is 
not surprising considering that the small size of the particle and accumulation of 
the nanoparticles was mainly caused by passive entrapment through the discontinuous 
endothelium of the liver. The 20% PEG coating in the formulation is stable in the biological 
environment (data not shown here) and would be sufficient to effectively block the 
adsorption of opsonic proteins at the early time of period after injection. The substrate lipid 
could influence the rate of clearance in the β phase. LCP-DOPC NPs possessed a longer half-
life at the β phase than their DOTAP counterparts.  
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Figure 5.1. Pharmacokinetics of LCP NPs with different lipid in normal and tumor-
bearing mice.  
Data are plotted as % injected dose vs time (N=4). PEG concentration is 20% (molar percent 
of outer leaflet lipids).  
The data of LCP-DOPC NPs is Figure 4.1. The data was placed here for easy comparison 
with that of LCP-DOTAP NPs.  
 
5.3.2 Tissue distribution 
Figure 5.2 shows the tissue distribution of LCP NPs at 4 h post-injection. The 
particles were distributed mainly in the liver, spleen and tumor. This observation is consistent 
with the fact that these tissues are lined with discontinuous or leaky endothelium that allows 
for passive entrapment of foreign particulates [118]. Despite the accumulation in the tumor, 
biodistribution profiles of the LCP NPs in tumor bearing mice were not significantly 
different from their normal controls.  The substrate lipid didn’t change the global tissue 
distribution pattern significantly. It is interesting to note that, however, the accumulation 
level of NPs was greatly enhanced in the liver by DOTAP compared with that of DOPC 
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(60% ID versus 30% ID). It is likely that the faster clearance of LCP-DOTAP NPs in the β 
phase is due to this enhanced uptake by liver.  
 
 
Figure 5.2 Tissue distribution of LCP NPs with different lipid. 
(A: normal mice; B: tumor-bearing mice. N=4)  Data are plotted as % injected dose vs time.  
The outer leaflet lipid is DOPC. PEG concentration is 20% (molar percent of outer leaflet 
lipids).  
5.3.3 Cell-type specific distribution 
To obtain direct evidence whether LCP NPs entered hepatocytes or were sequestered 
by kupffer cells in vivo, we injected mice with LCP NPs containing Texas Red-labeled 
oligonucleotide and observed the tissue sections under confocal microscopy. Cell-type 
specific distribution and the lipid dependence of hepatic delivery were investigated. Confocal 
microscopy of liver sections taken from mice 4 h after the injection of NPs are shown in 
Figure 5.3. Tissue sections were stained with Alexa488-phalloidin (green) to visualize cell 
membranes of hepatocytes and with DAPI (blue) for all nuclei. Preferential accumulation of 
the Texas Red-labeled oligonucleotide in hepatocytes was observed in mice injected with 
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LCP-DOTAP NPs. Only minor amounts of signal were associated with nonparenchymal cells 
in the liver sinusoids (Figure 5.3B and C). Distribution was generally homogenous 
throughout the different zones and the liver lobules. Replacement of DOTAP on the NPs 
with DOPC resulted in markedly reduced hepatocyte uptake (Figure 5.3C).  
 
    
Figure 5.3 Cell-type specific localization of LCP NPs with different lipid in liver.  
DAPI for nuclei, Alexa 488 for phalloidin, and Texas Red for oligonucleotides. DOPC and 
DOTAP were in the outer leaflet of the wrapping lipid bilayer of LCP NPs, respectively.  
 
5.3.4 Composition of protein corona 
To investigate the mechanisms causing higher uptake of LCP-DOTAP NPs by 
hepatocytes, LCP-DOTAP and DOPC NPs with different amounts of PEGylation were 
incubated with serum. The resulting protein corona was analyzed for protein identification. 
The NP-protein complexes were washed three times to get rid of the proteins with low 
affinity for the NP surface. NPs were incubated with 20% or 80% serum. The higher protein: 
nanoparticle ratio may be more representative of the true biological conditions in the 
bloodstream. 
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SDS-PAGE gel of serum proteins obtained from the LCP NP-protein complexes is 
shown in Figure 5.4. The main spots on the gels were HSA, IgG, and the apolipoproteins. 
Particles made of DOPC with a different PEG density exhibited similar qualitative 
compositions of their plasma protein adsorption patterns. This observation was consistent 
with some literature indicating that despite the net decrease in the amount of proteins bound 
with PEGylated NPs, protein profiles of the PEGylated NPs were not significantly different 
than their uncoated controls [117]. For LCP-DOTAP NPs with 5%, specific bands of 
apolipoproteins apo E and apo A-II (Figure 5.4, band 5and 7) were observed. Besides, when 
increasing the PEG content in the NPs to 20 %, a decrease in Complement C3 adsorption was 
achieved. We hypothesize that LCP NPs with 20% PEG could gradually shed off PEG 
coating after administration, due to the sink conditions provided by the serum proteins, 
exposing the substrate lipid. Once attached to the surface of hepatocytes, LCP-DOTAP NPs 
with apo E can enter the cells via receptor-mediated endocytosis. In contrast, LCP-DOPC 
NPs were merely transiently associated with the liver and were re-distributed out of this 
organ without significant internalization.  
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Figure 5.4 SDS-PAGE gel of serum proteins obtained from LCP NP-protein complexes 
following incubation at different serum concentrations. 
The molecular weights of the proteins in the standard ladder are reported on the right for 
reference. The numbers reported close to the gel bands for LCP-DOTAP NPs with 5% PEG 
in 80% serum indicate that those bands were cut out and analyzed with MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 81 
 
Table 5.1 Representative proteins associated with LCP-DOTAP NPs with 5% PEG 
incubated in 80% serum, as identified by LC MS/MS.  
 
 
5.3.5 in vivo apoE dependency   
To determine whether apoE is indeed responsible for the specific delivery of LCP 
NPs to hepatocytes, biodistribution studies were performed in wild-type and apoE−/− mice. 
The biodistribution in apoE−/− mice demonstrated identical levels in hepatic accumulation 
between LCP-DOTAP and LCP-DOPC NPs (Figure. 5.5). In contrast, in wide type mice, 
LCP-DOTAP NPs mediated an enhanced accumulation of the dose in the liver. No 
significant difference was found in the detected signals in other major organs. These results 
validated the findings of our protein adsorption studies and suggested that the targeting of 
LCP-DOTAP NPs to hepatocytes may be apo E-denpendent.  
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Figure 5.5 Tissue distribution of LCP NPs in wild-type and apoE−/− mice (N=4). 
** indicates p<0.05 Formulations: LCP-DOPC and LCP-DOTAP NPs with 20% PEG. 
5.4 DISCUSSION 
The results presented in this chapter suggest that apoE acts as an endogenous 
targeting ligand and plays a major role in the β-phase of plasma clearance and hepatic uptake 
of LCP NPs. LCP-DOTAP NPs were taken up by hepatocytes more than LCP-DOPC NPs. 
Protein adsorption studies demonstrated that apoE adsorption occurred specifically in LCP-
DOTAP NPs. These findings were corroborated by in vivo studies in wild-type and apoE−/− 
mice. The difference in hepatocyte uptake of LCP-DOTAP and LCP-DOPC NP observed in 
wild-type mice was almost completely absent in apoE−/− mice. The relatively large variation 
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of liver uptake in apoE−/− mice might be due to the alterations in gene expression profile and 
serum lipoprotein composition. 
It has been reported that cationic lipid-based NPs may recruit apoE as an endogenous 
ligand in vivo. Multiple receptors have been associated with apoE-mediated uptake, such as 
low-density lipoprotein receptors (LDLR), many other members of the LDLR, and scavenger 
receptors, which are also expressed on the surface of hepatocytes. These systems usually 
contain a total PEG–lipid in the formulation less than 5 mol% [119]. It is interesting to note 
that with 20% PEG on the surface, the substrate lipid still plays a critical role in determining 
the in vivo fate of NPs. One possible explanation is that the PEG coating gradually sheds off 
in circulation and the presence of surface charge may facilitate specific protein-membrane 
interaction. 
About 80% of liver cells are hepatocytes, which constitute the parenchyma of the 
liver tissues, and the others are non-parenchymal cells, including Kupffer cells, endothelial 
cells, extrathymic T cells localized in sinusoids, and Ito cells (also called stellate cells) 
localized in the space of Disse [120]. The blood flow after tail vein injection of LCP NPs 
circulates from the portal vein to the sinusoids then to the central veins. In mice, the LCP 
NPs delivered by this method could potentially extravasate to space of Disse via the fenestrae 
with size of about 150 nm in the liver sinusoidal endothelium [121], where the particles come 
into direct contact with hepatocytes.  If the particles are still densely coated with PEG, they 
will not be taken up by the hepatocytes and may re-enter circulation. K13 and K31 are the 
intercompartmental transfer rate constants between the peripheral compartment (liver) and 
the central compartment (blood), respectively. As the PEG molecules on the surface diffuse, 
gradually exposing the surface lipid to the in vivo environment, the protein corona starts to 
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form on the surface of the particles, where apo E begins to have an effect as an endogenous 
targeting ligand. LCP-DOTAP NPs could be internalized by the hepatocytes through 
receptors such as LDLR through the process of receptor-mediated endocytosis, whereas 
LCP-DOPC NPs may only enter the hepatocytes through non-specific interactions.  It is 
likely that LCP-DOPC NPs that are not taken up to a significant degree by hepatocytes may 
re-enter circulation, resulting in a slow clearance in β-phase. The hypothesized mechanism of 
hepatocyte uptake of LCP-DOTAP and LCP-DOPC NPs was summarized in Figure 5.6. 
A key drawback of this method of targeting, however, is that the NPs rely on 
endogenous apo E. As a result, LCP NPs delivered to target cells in the liver might be 
variable, potentially contributing to toxicity. Attachment of a targeting ligand such as 
galactose onto the NPs may facilitate hepatocyte targeting and prevent unexpected side 
effects. Identification and selection of the best markers to differentiate liver parenchymal and 
non-parenchymal regions are crucial to the success of delivery of LCP NPs to hepatocytes. A 
series of hepatocyte markers should be tested to determine their targeting effects.  
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Figure 5.6 Hypothesized mechanism of hepatocytes uptake of LCP-DOTAP and LCP-
DOPC NPs. 
  
CHAPTER 6 
DISCUSSION 
6.1 SUMMARY OF RESEARCH RESULTS AND FUTURE PLANS 
It is known that the successful development of nanoparticulate therapeutics relies on 
the in-depth understanding of their in vivo PK and biodistribution, determined by a series of 
properties of NPs. Here we established a relationship between the physicochemical properties 
of LCP NPs and their in vivo PK and biodistribution profiles, which may provide important 
information for an approach to rational formulation development. The PK and biodistribution 
studies were conducted using careful method validation (Chapter 2).  
With a supported lipid bilayer structure, the LCP NP could accommodate a high 
degree of PEGylation compared to the conventional liposomes containing a regular lipid 
bilayer.  We have shown that approximately 20 mol% of the outer leaflet of the lipid 
membrane was modified with DSPE-PEG2000, creating an inter- and intramolecular, 
entangled PEG layer on the surface of the NPs (Chapter 3).  This densely coated LCP NP 
showed a biphasic elimination pattern in PK. The rapid clearance in the α-phase was due to 
extravasation of the NPs to highly fenestrated tissues, such as the liver. Within the liver, LCP 
NPs delivered cargo to hepatocytes in a PEG concentration-dependent manner, revealed by 
confocal imaging. A high-density PEG coating enables hepatocyte delivery and avoidance of 
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RES uptake, although whether the hepatocyte uptake is specific to lipid-based NPs is still 
unknown (Chapter 4).  
Additionally, LCP NPs with surface coatings of different lipids exhibit different in 
vivo behaviors after intravenous injections. LCP NPs modified with DOTAP exhibited higher 
accumulation in the liver than LCP NPs modified with DOPC. These altered 
pharmacokinetic and biodistribution properties are the product of protein binding patterns of 
the surface lipids. Analysis of NP-bound proteins revealed that apoE might serve as an 
endogenous targeting ligand for LCP-DOTAP NPs, but not for LCP-DOPC NPs. The 
enhanced liver accumulation of LCP-DOTAP NPs was reduced in apoE deficient mice. Thus, 
in vitro characterization obtained after the incubation of the NP-protein complexes might be 
predictive of the behavior observed in vivo (Chapter 5). 
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6.2 FURTHER DIRECTIONS 
Our future plan is to 1) further optimize the formulation to enhance the antitumor 
effect of these particles and 2) utilize the formulation in a suitable liver disease model.  
 LCP NPs present a convenient platform to incorporate multiple functionalities for 
cancer therapeutics or imaging. An in-depth understanding of the interactions between NPs 
and biological systems is of significant interest. Our further studies are aimed at correlating 
the properties of LCP NPs, such as size, PEGylation and targeting ligands, with blood 
kinetics, tissue distribution, transportation, and therapeutic or imaging performances. By 
identifying how size, PEGylation and targeting ligands influence the delivery process, we 
may then be able to redesign the nanoparticle formulation to maximize accumulation in the 
tumor (either primary or metastatic). First, we plan to modify the preparation method of LCP 
NPs to make a series of NPs with different sizes and determine the optimal size for tumor 
delivery. Second, we plan to employ PEG molecules with different chain lengths. We are 
going to investigate the effects of low graft densities with high molecular weight PEG vs. the 
higher surface density of low molecular weight polymers on reducing protein adsorption. The 
conformation of the grafted PEG will also be investigated. Third, we plan to test a series of 
targeting ligands to enhance to tumor delivery. Recent studies suggested that PEG surface 
density of NPs had a significant effect on ligand-directed tumor targeting. The highest 
specificity and targeting efficiency was observed at a low PEG surface density [122]. With 
well-designed new formulations and further additions of targeting ligand, the performance of 
LCP NPs on cancer treatment and diagnostics could be improved. 
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LCP NPs, in particular LCP-DOTAP NPs, exhibited significant accumulation in the 
liver. NPs delivered in sinusoids or engulfed by Kupffer cells are generally inactive for 
therapeutic effects and might cause toxicity, However, the hepatocytes are often the cell type 
of interest for therapeutic application. Many liver diseases, for example, hepatitis B virus 
infections, hepatocellular carcinoma and liver cirrhosis, pose a serious health challenge 
worldwide due to the lack of curative treatment options other than liver resection or 
transplantation.  
First, we plan to utilize RNAi therapeutics by using LCP NPs to treat hepatocellular 
carcinomas. Multiple siRNAs could be encapsulated into a single LCP NP to acheive 
combination therapy. Second, many antivirus drugs are nucleoside analogues. They can be 
phosphorylated to form prodrugs and encapsulated into the CaP core of LCP NPs. For long-
term clinical application, toxicity would be a primary concern. While the size and surface 
chemistry are important for their in vivo behavior, composition of the NPs is mainly 
responsible for cytotoxicity. Since calcium phosphate is the principle building component of 
hard tissues such as bone and tooth enamel, calcium and phosphate ions already exist in the 
body at millimolar concentrations. The biodegradation products of LCP NPs are thus 
presumed to be relatively nontoxic. The major concern for the toxicity might be derived from 
the lipid.  
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6.3 ENDING REMARKS 
Engineered NPs offer an unprecedented opportunity for therapeutic and diagnostic 
applications. To design the most efficient nanoparticle-based delivery systems, nano-bio 
interactions must be carefully investigated. Not only will the results facilitate the engineering 
of NPs, but they will also help our understanding in the morphology and chemistry of 
nanoscale objects in mediating biological responses. The fundamental studies on nano-bio 
interactions will enable an approach to the rational formulation development and the 
nanoengineering process by creating specific design rules. This would also provide a 
perspective on the construction of complex nanostructures that ensure the highest possible 
delivery efficiency. In vitro characterization of NPs and correlation to their in vivo fate could 
also lead to the development of predictive and simulation tools to assist in the engineering 
process. 
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APPENDIX A 
Theory of small angel neutron scattering for polymer analysis 
 
A typical neutron diffractometer consists of a source of radiation, a monochromator 
to select the wavelength, slits to adjust the shape of the beam, a sample and a detector. As 
shown in Figure A1, during a SANS experiment, a beam of neutrons from a reactor is 
slowed down and properly selected by their speed. The neutrons are then directed at a 
sample, which can be either an aqueous solution or a solid sample. The neutrons are 
elastically scattered by nuclear interaction with the nuclei or interaction with magnetic 
momentum of unpaired electrons. An area detector is used to monitor the diffracted radiation 
and the position of detector can be adjusted. In zero order dynamical theory of diffraction, 
the strength of the interaction of a neutron wave with a given nucleus is directly related to the 
scattering length density (SLD). Different types of system have different natural patterns for 
the distribution of SLD. In the case of polymer systems, where we have countable repeated 
units that make up the scattering, we can think about the spatial distribution of those units 
such that the structure of the polymer might be revealed. The scattering length of nuclei 
varies randomly across the periodic table and between isotopes of the same element. PEG 
conformation study utilized the technique of contrast variation (or contrast matching), which 
takes advantages of the differential scatter of hydrogen and deuterium.  
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Figure A1. Schematic illustration of general-purpose SANS diffractometer. 
(Picture from www. ornl. gov) 
 
In neutron scattering experiments, the momentum transfer (q) for the incident neutron 
and the scattered neutron were recorded (as shown in Figure A2), where q = ki - ks with ki 
and ks being the wavevectors of the incoming and scattered neutrons respectively. Scientists 
measure the intensity of neutrons scattered by matter (per incident neutron) as a function of 
the variable q. The scattered intensity is often denoted as I (q).  
 
 
Figure A2. Schematic representation of the momentum initial state and final state 
during elastic scattering. 
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There are essentially two classes of data analysis: model-dependent and model-independent. 
In this study, we used the former method, which consists of building a mathematical model 
of the SLD distribution to describe the spatial arrangement of the material in the sample. 
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                                                                APPENDIX B 
Yang Liu’s publications 
Peer-reviewed Papers 
• Liu Y, Huang L. Influence of lipid composition on pharmacokinetics and 
biodistribution of LCP Nanoparticles  Manuscript in Preparation 
• Liu Y, Nieh MP, Heller W, Hu Y, Huang L. Nanoparticle delivery to hepatocytes 
requires a compact, non-brush conformation of the polyethylene glycol coating. In 
revision 
• Liu Y, Tseng YC, Huang L. Biodistribution studies of nanoparticles using fluorescent 
imaging: A qualitative or quantitative method? Pharm Res. 2012 Jul 18.  
• Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance 
in cancer. Mol Pharm. 2010;7(3):863-9. 
• Liu F, Park JY, Zhang Y, Conwell C, Liu Y, Bathula SR, Huang L. Targeted cancer 
therapy with novel high drug-loading nanocrystals. J Pharm Sci. 2010;99(8):3542-51. 
• Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ. 
Doxorubicin and Paclitaxel-loaded Lipid-based Nanoparticles Overcome Multi-Drug 
Resistance by Inhibiting P-gp and Depleting ATP. Cancer Res. 2009;69(9):3918-26. 
 
Review Papers and Perspectives 
• Huang L, Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev 
Biomed Eng. 2011;13:507-30. 
• Liu Y, Huang L. Designer lipids advance systemic siRNA delivery. Mol Ther. 
2010;18(4):669-70. 
Conference Abstracts 
• Yang Liu, Mu-Ping Nieh, William Heller, Yunxia Hu and Leaf Huang. Nanoparticle 
delivery to hepatocytes requires a compact, non-brush conformation of the 
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polyethylene glycol coating. Drug Carriers in Medicine & Biology, Gordon Research 
Conferences. Waterville Valley, NH, August 2012. Poster Presentation 
• Yang Liu, Leaf Huang and Feng Liu. Paclitaxel nanocrystals for overcoming 
multidrug resistance in cancer. Liposome Research Days Conference, Vancouver, 
Canada, August 2010. Poster Presentation 
 
 
 96 
 
REFERENCES 
1. Davis, M.E., Z.G. Chen, and D.M. Shin, Nanoparticle therapeutics: an emerging 
treatment modality for cancer. Nat Rev Drug Discov, 2008. 7(9): p. 771-82. 
2. Reddy, L.H. and P. Couvreur, Nanotechnology for therapy and imaging of liver 
diseases. J Hepatol, 2011. 55(6): p. 1461-6. 
3. Jain, R.K. and T. Stylianopoulos, Delivering nanomedicine to solid tumors. Nat Rev 
Clin Oncol, 2010. 7(11): p. 653-64. 
4. Rosen, H. and T. Abribat, The rise and rise of drug delivery. Nat Rev Drug Discov, 
2005. 4(5): p. 381-5. 
5. Wagner, V., et al., The emerging nanomedicine landscape. Nat Biotechnol, 2006. 
24(10): p. 1211-7. 
6. Wolff, J.A. and D.B. Rozema, Breaking the bonds: non-viral vectors become 
chemically dynamic. Mol Ther, 2008. 16(1): p. 8-15. 
7. Bragonzi, A., et al., Biodistribution and transgene expression with nonviral cationic 
vector/DNA complexes in the lungs. Gene Ther, 2000. 7(20): p. 1753-60. 
8. Ishiwata, H., et al., Characteristics and biodistribution of cationic liposomes and 
their DNA complexes. J Control Release, 2000. 69(1): p. 139-48. 
9. Ishida, O., et al., Size-dependent extravasation and interstitial localization of 
polyethyleneglycol liposomes in solid tumor-bearing mice. Int J Pharm, 1999. 190(1): 
p. 49-56. 
10. Whitehead, K.A., R. Langer, and D.G. Anderson, Knocking down barriers: advances 
in siRNA delivery. Nat Rev Drug Discov, 2009. 8(2): p. 129-38. 
11. Di Guglielmo, G.M., et al., Distinct endocytic pathways regulate TGF-beta receptor 
signalling and turnover. Nat Cell Biol, 2003. 5(5): p. 410-21. 
12. Fang, C., et al., In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth 
nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci, 
2006. 27(1): p. 27-36. 
13. Alexis, F., et al., Factors affecting the clearance and biodistribution of polymeric 
nanoparticles. Mol Pharm, 2008. 5(4): p. 505-15. 
 97 
 
14. Braet, F. and E. Wisse, Structural and functional aspects of liver sinusoidal 
endothelial cell fenestrae: a review. Comp Hepatol, 2002. 1(1): p. 1. 
15. Braet, F., et al., Contribution of high-resolution correlative imaging techniques in the 
study of the liver sieve in three-dimensions. Microsc Res Tech, 2007. 70(3): p. 230-
42. 
16. Matsumura, Y. and H. Maeda, A new concept for macromolecular therapeutics in 
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the 
antitumor agent smancs. Cancer Res, 1986. 46(12 Pt 1): p. 6387-92. 
17. Hobbs, S.K., et al., Regulation of transport pathways in tumor vessels: role of tumor 
type and microenvironment. Proc Natl Acad Sci U S A, 1998. 95(8): p. 4607-12. 
18. Jain, R.K., Delivery of molecular medicine to solid tumors. Science, 1996. 271(5252): 
p. 1079-80. 
19. Olive, K.P., et al., Inhibition of Hedgehog signaling enhances delivery of 
chemotherapy in a mouse model of pancreatic cancer. Science, 2009. 324(5933): p. 
1457-61. 
20. Xiao, K., et al., The effect of surface charge on in vivo biodistribution of PEG-
oligocholic acid based micellar nanoparticles. Biomaterials, 2011. 32(13): p. 3435-
46. 
21. Schipper, M.L., et al., Particle size, surface coating, and PEGylation influence the 
biodistribution of quantum dots in living mice. Small, 2009. 5(1): p. 126-34. 
22. Thorek, D.L. and A. Tsourkas, Size, charge and concentration dependent uptake of 
iron oxide particles by non-phagocytic cells. Biomaterials, 2008. 29(26): p. 3583-90. 
23. Roser, M., D. Fischer, and T. Kissel, Surface-modified biodegradable albumin nano- 
and microspheres. II: effect of surface charges on in vitro phagocytosis and 
biodistribution in rats. Eur J Pharm Biopharm, 1998. 46(3): p. 255-63. 
24. Jokerst, J.V., et al., Nanoparticle PEGylation for imaging and therapy. Nanomedicine 
(Lond), 2011. 6(4): p. 715-28. 
25. Owens, D.E., 3rd and N.A. Peppas, Opsonization, biodistribution, and 
pharmacokinetics of polymeric nanoparticles. Int J Pharm, 2006. 307(1): p. 93-102. 
26. Moghimi, S.M. and J. Szebeni, Stealth liposomes and long circulating nanoparticles: 
critical issues in pharmacokinetics, opsonization and protein-binding properties. 
Prog Lipid Res, 2003. 42(6): p. 463-78. 
 98 
 
27. Yamamoto, Y., et al., Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block 
copolymer micelles with modulated surface charge. J Control Release, 2001. 77(1-2): 
p. 27-38. 
28. Chung, T.H., et al., The effect of surface charge on the uptake and biological function 
of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem 
cells. Biomaterials, 2007. 28(19): p. 2959-66. 
29. Lopes de Menezes, D.E., L.M. Pilarski, and T.M. Allen, In vitro and in vivo targeting 
of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res, 1998. 
58(15): p. 3320-30. 
30. Zhou, Y., et al., Impact of single-chain Fv antibody fragment affinity on nanoparticle 
targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol, 
2007. 371(4): p. 934-47. 
31. Farokhzad, O.C., et al., Nanoparticle-aptamer bioconjugates: a new approach for 
targeting prostate cancer cells. Cancer Res, 2004. 64(21): p. 7668-72. 
32. Stella, B., et al., Design of folic acid-conjugated nanoparticles for drug targeting. J 
Pharm Sci, 2000. 89(11): p. 1452-64. 
33. Montet, X., et al., Multivalent effects of RGD peptides obtained by nanoparticle 
display. J Med Chem, 2006. 49(20): p. 6087-93. 
34. Tokatlian, T. and T. Segura, siRNA applications in nanomedicine. Wiley Interdiscip 
Rev Nanomed Nanobiotechnol. 2(3): p. 305-15. 
35. Bartlett, D.W., et al., Impact of tumor-specific targeting on the biodistribution and 
efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc 
Natl Acad Sci U S A, 2007. 104(39): p. 15549-54. 
36. Kirpotin, D.B., et al., Antibody targeting of long-circulating lipidic nanoparticles 
does not increase tumor localization but does increase internalization in animal 
models. Cancer Res, 2006. 66(13): p. 6732-40. 
37. Li, S.D. and L. Huang, Stealth nanoparticles: high density but sheddable PEG is a 
key for tumor targeting. J Control Release. 145(3): p. 178-81. 
38. Geng, Y. and D.E. Discher, Hydrolytic degradation of poly(ethylene oxide)-block-
polycaprolactone worm micelles. J Am Chem Soc, 2005. 127(37): p. 12780-1. 
39. Park, J.H., et al., Systematic surface engineering of magnetic nanoworms for in vivo 
tumor targeting. Small, 2009. 5(6): p. 694-700. 
40. Decuzzi, P., et al., A theoretical model for the margination of particles within blood 
vessels. Ann Biomed Eng, 2005. 33(2): p. 179-90. 
 99 
 
41. Flory, P.J., Principles of Polymer Chemistry. 1971: Cornell Univ. Press, Ithaca, NY. 
42. de Gennes, P., Conformations of polymers attached to an interface. Macromolecules, 
1980. 13(5): p. 1069-1075. 
43. Vonarbourg, A., et al., Parameters influencing the stealthiness of colloidal drug 
delivery systems. Biomaterials, 2006. 27(24): p. 4356-73. 
44. Zolnik, B.S. and N. Sadrieh, Regulatory perspective on the importance of ADME 
assessment of nanoscale material containing drugs. Adv Drug Deliv Rev, 2009. 
61(6): p. 422-7. 
45. Jun, Y.W., et al., Surfactant-assisted elimination of a high energy facet as a means of 
controlling the shapes of TiO2 nanocrystals. J Am Chem Soc, 2003. 125(51): p. 
15981-5. 
46. Marsh, D., R. Bartucci, and L. Sportelli, Lipid membranes with grafted polymers: 
physicochemical aspects. Biochim Biophys Acta, 2003. 1615(1-2): p. 33-59. 
47. Kenworthy, A.K., et al., Range and magnitude of the steric pressure between bilayers 
containing phospholipids with covalently attached poly(ethylene glycol). Biophys J, 
1995. 68(5): p. 1921-36. 
48. Bedu-Addo, F.K., et al., Effects of polyethyleneglycol chain length and phospholipid 
acyl chain composition on the interaction of polyethyleneglycol-phospholipid 
conjugates with phospholipid: implications in liposomal drug delivery. Pharm Res, 
1996. 13(5): p. 710-7. 
49. Shimada, K., et al., Determination of incorporated amounts of poly(ethylene glycol)-
derivatized lipids in liposomes for the physicochemical characterization of stealth 
liposomes. Int J Pharm, 2000. 203(1-2): p. 255-63. 
50. Kingshott, P., H. Thissen, and H.J. Griesser, Effects of cloud-point grafting, chain 
length, and density of PEG layers on competitive adsorption of ocular proteins. 
Biomaterials, 2002. 23(9): p. 2043-56. 
51. Li, S.D. and L. Huang, Nanoparticles evading the reticuloendothelial system: role of 
the supported bilayer. Biochim Biophys Acta, 2009. 1788(10): p. 2259-66. 
52. Li, S.D. and L. Huang, Pharmacokinetics and biodistribution of nanoparticles. Mol 
Pharm, 2008. 5(4): p. 496-504. 
53. Li, S.D., S. Chono, and L. Huang, Efficient oncogene silencing and metastasis 
inhibition via systemic delivery of siRNA. Mol Ther, 2008. 16(5): p. 942-6. 
54. Zalipsky, S., Functionalized poly(ethylene glycol) for preparation of biologically 
relevant conjugates. Bioconjug Chem, 1995. 6(2): p. 150-65. 
 100 
 
55. Parrish, B., R.B. Breitenkamp, and T. Emrick, PEG- and peptide-grafted aliphatic 
polyesters by click chemistry. J Am Chem Soc, 2005. 127(20): p. 7404-10. 
56. Ishida, T., D.L. Iden, and T.M. Allen, A combinatorial approach to producing 
sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett, 1999. 460(1): p. 
129-33. 
57. Liu, Z., et al., Circulation and long-term fate of functionalized, biocompatible single-
walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci 
U S A, 2008. 105(5): p. 1410-5. 
58. Chan, J.M., et al., PLGA-lecithin-PEG core-shell nanoparticles for controlled drug 
delivery. Biomaterials, 2009. 30(8): p. 1627-34. 
59. Dubertret, B., et al., In vivo imaging of quantum dots encapsulated in phospholipid 
micelles. Science, 2002. 298(5599): p. 1759-62. 
60. Xia, X., et al., Quantifying the coverage density of poly(ethylene glycol) chains on the 
surface of gold nanostructures. ACS Nano, 2012. 6(1): p. 512-22. 
61. Garbuzenko, O., Y. Barenholz, and A. Priev, Effect of grafted PEG on liposome size 
and on compressibility and packing of lipid bilayer. Chem Phys Lipids, 2005. 135(2): 
p. 117-29. 
62. Levin, C.S., et al., Determining the conformation of thiolated poly(ethylene glycol) on 
Au nanoshells by surface-enhanced Raman scattering spectroscopic assay. Anal 
Chem, 2006. 78(10): p. 3277-81. 
63. Garcia-Fuentes, M., et al., Application of NMR spectroscopy to the characterization 
of PEG-stabilized lipid nanoparticles. Langmuir, 2004. 20(20): p. 8839-45. 
64. Hayter, J.B., Physics of Amphiphiles--Micelles, Vesicles, and Microemulsions. 1983. 
65. Engel, M.F., A.J. Visser, and C.P. van Mierlo, Conformation and orientation of a 
protein folding intermediate trapped by adsorption. Proc Natl Acad Sci U S A, 2004. 
101(31): p. 11316-21. 
66. Cedervall, T., et al., Understanding the nanoparticle-protein corona using methods to 
quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad 
Sci U S A, 2007. 104(7): p. 2050-5. 
67. Mahmoudi, M., et al., Protein-nanoparticle interactions: opportunities and 
challenges. Chem Rev, 2011. 111(9): p. 5610-37. 
68. Nel, A.E., et al., Understanding biophysicochemical interactions at the nano-bio 
interface. Nat Mater, 2009. 8(7): p. 543-57. 
 101 
 
69. Cedervall, T., et al., Detailed identification of plasma proteins adsorbed on 
copolymer nanoparticles. Angew Chem Int Ed Engl, 2007. 46(30): p. 5754-6. 
70. Moghimi, S.M., A.C. Hunter, and T.L. Andresen, Factors controlling nanoparticle 
pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol 
Toxicol, 2012. 52: p. 481-503. 
71. Klein, J., Probing the interactions of proteins and nanoparticles. Proc Natl Acad Sci 
U S A, 2007. 104(7): p. 2029-30. 
72. Aggarwal, P., et al., Nanoparticle interaction with plasma proteins as it relates to 
particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv 
Rev, 2009. 61(6): p. 428-37. 
73. Norman, M.E., P. Williams, and L. Illum, Influence of block copolymers on the 
adsorption of plasma proteins to microspheres. Biomaterials, 1993. 14(3): p. 193-
202. 
74. Kim, H.R., et al., Analysis of plasma protein adsorption onto PEGylated 
nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip 
system. Electrophoresis, 2007. 28(13): p. 2252-61. 
75. Ogawara, K., et al., Pre-coating with serum albumin reduces receptor-mediated 
hepatic disposition of polystyrene nanosphere: implications for rational design of 
nanoparticles. J Control Release, 2004. 100(3): p. 451-5. 
76. Moghimi, S.M. and A.C. Hunter, Recognition by macrophages and liver cells of 
opsonized phospholipid vesicles and phospholipid headgroups. Pharm Res, 2001. 
18(1): p. 1-8. 
77. Taylor, P.R., et al., Macrophage receptors and immune recognition. Annu Rev 
Immunol, 2005. 23: p. 901-44. 
78. Olivier, J.C., Drug transport to brain with targeted nanoparticles. NeuroRx, 2005. 
2(1): p. 108-19. 
79. Klibanov, A.L., et al., Amphipathic polyethyleneglycols effectively prolong the 
circulation time of liposomes. FEBS Lett, 1990. 268(1): p. 235-7. 
80. Blume, G. and G. Cevc, Liposomes for the sustained drug release in vivo. Biochim 
Biophys Acta, 1990. 1029(1): p. 91-7. 
81. Papahadjopoulos, D., et al., Sterically stabilized liposomes: improvements in 
pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A, 
1991. 88(24): p. 11460-4. 
 102 
 
82. Michel, R., et al., Influence of PEG architecture on protein adsorption and 
conformation. Langmuir, 2005. 21(26): p. 12327-32. 
83. Fang, F., J. Satulovsky, and I. Szleifer, Kinetics of protein adsorption and desorption 
on surfaces with grafted polymers. Biophys J, 2005. 89(3): p. 1516-33. 
84. Cullis, P.R., A. Chonn, and S.C. Semple, Interactions of liposomes and lipid-based 
carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv 
Drug Deliv Rev, 1998. 32(1-2): p. 3-17. 
85. Poon, Z., et al., Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo 
targeting of tumor hypoxia. ACS Nano, 2011. 5(6): p. 4284-92. 
86. Lee, E.S., Z. Gao, and Y.H. Bae, Recent progress in tumor pH targeting 
nanotechnology. J Control Release, 2008. 132(3): p. 164-70. 
87. Sarkar, N., et al., Matrix metalloproteinase-assisted triggered release of liposomal 
contents. Bioconjug Chem, 2008. 19(1): p. 57-64. 
88. Wong, C., et al., Multistage nanoparticle delivery system for deep penetration into 
tumor tissue. Proc Natl Acad Sci U S A, 2011. 108(6): p. 2426-31. 
89. Wu, G., et al., Remotely triggered liposome release by near-infrared light absorption 
via hollow gold nanoshells. J Am Chem Soc, 2008. 130(26): p. 8175-7. 
90. Paasonen, L., et al., Gold nanoparticles enable selective light-induced contents 
release from liposomes. J Control Release, 2007. 122(1): p. 86-93. 
91. von Maltzahn, G., et al., Nanoparticles that communicate in vivo to amplify tumour 
targeting. Nat Mater, 2011. 10(7): p. 545-52. 
92. Juliano, R., Challenges to macromolecular drug delivery. Biochem Soc Trans, 2007. 
35(Pt 1): p. 41-3. 
93. Agrawal, S., J. Temsamani, and J.Y. Tang, Pharmacokinetics, biodistribution, and 
stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S 
A, 1991. 88(17): p. 7595-9. 
94. Nakada, Y., et al., Pharmacokinetics and biodistribution of oligonucleotide adsorbed 
onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in 
mice. Pharm Res, 1996. 13(1): p. 38-43. 
95. Beverly, M.B., Applications of mass spectrometry to the study of siRNA. Mass 
Spectrom Rev. 30(6): p. 979-98. 
 103 
 
96. Chen, G., et al., Characterization of protein therapeutics by mass spectrometry: 
recent developments and future directions. Drug Discov Today, 2011. 16(1-2): p. 58-
64. 
97. Frangioni, J.V., In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol, 
2003. 7(5): p. 626-34. 
98. Hilderbrand, S.A. and R. Weissleder, Near-infrared fluorescence: application to in 
vivo molecular imaging. Curr Opin Chem Biol. 14(1): p. 71-9. 
99. Li, J., Y. Yang, and L. Huang, Calcium phosphate nanoparticles with an asymmetric 
lipid bilayer coating for siRNA delivery to the tumor. J Control Release. 
100. Mackiewicz, N., et al., Tumor-targeted polydiacetylene micelles for in vivo imaging 
and drug delivery. Small, 2011. 7(19): p. 2786-92. 
101. Abdelmawla, S., et al., Pharmacological characterization of chemically synthesized 
monomeric phi29 pRNA nanoparticles for systemic delivery. Mol Ther, 2011. 19(7): 
p. 1312-22. 
102. Goldberg, M.S., et al., Nanoparticle-mediated delivery of siRNA targeting Parp1 
extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer 
cells. Proc Natl Acad Sci U S A, 2011. 108(2): p. 745-50. 
103. Yang, Y., et al., Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits 
lung metastasis. Mol Ther, 2012. 20(3): p. 609-15. 
104. Graham, M.J., et al., Tritium labeling of antisense oligonucleotides by exchange with 
tritiated water. Nucleic Acids Res, 1993. 21(16): p. 3737-43. 
105. Ballou, B., L.A. Ernst, and A.S. Waggoner, Fluorescence imaging of tumors in vivo. 
Curr Med Chem, 2005. 12(7): p. 795-805. 
106. Zhao, J.K., Gao, C. Y., Liu, D. , The extended Q-range small-angle neutron 
scattering diffractometer at the SNS. Journal of Applied Crystallography, 2010. 43: p. 
1068-1077. 
107. Kline, S.R., Reduction and analysis of SANS and USANS data using IGOR Pro. 
Journal of Applied Crystallography 2006. 39: p. 895-900. 
108. Damodaran, V.B., et al., Conformational studies of covalently grafted poly(ethylene 
glycol) on modified solid matrices using X-ray photoelectron spectroscopy. 
Langmuir, 2010. 26(10): p. 7299-306. 
109. Gao, X., et al., Chain conformation of a new class of PEG-based thermoresponsive 
polymer brushes grafted on silicon as determined by neutron reflectometry. 
Langmuir, 2009. 25(17): p. 10271-8. 
 104 
 
110. Devanand, K. and J.C. Selser, Asymptotic behavior and long-range interactions in 
aqueous solutions of poly(ethylene oxide). Macromolecules, 1991. 24(22): p. 5943-
5947. 
111. Woodle, M.C. and D.D. Lasic, Sterically stabilized liposomes. Biochim Biophys 
Acta, 1992. 1113(2): p. 171-99. 
112. Swain, P.S. and D. Andelman, Supported membranes on chemically structured and 
rough surfaces. Phys Rev E Stat Nonlin Soft Matter Phys, 2001. 63(5 Pt 1): p. 
051911. 
113. Lipowsky, R., The conformation of membranes. Nature, 1991. 349(6309): p. 475-81. 
114. Allen, C., et al., Controlling the physical behavior and biological performance of 
liposome formulations through use of surface grafted poly(ethylene glycol). Biosci 
Rep, 2002. 22(2): p. 225-50. 
115. Cabral, H., et al., Accumulation of sub-100 nm polymeric micelles in poorly 
permeable tumours depends on size. Nat Nanotechnol, 2011. 6(12): p. 815-23. 
116. Monopoli, M.P., et al., Physical-chemical aspects of protein corona: relevance to in 
vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc, 2011. 133(8): 
p. 2525-34. 
117. Gref, R., et al., 'Stealth' corona-core nanoparticles surface modified by polyethylene 
glycol (PEG): influences of the corona (PEG chain length and surface density) and of 
the core composition on phagocytic uptake and plasma protein adsorption. Colloids 
Surf B Biointerfaces, 2000. 18(3-4): p. 301-313. 
118. Senior, J.H., Fate and behavior of liposomes in vivo: a review of controlling factors. 
Crit Rev Ther Drug Carrier Syst, 1987. 3(2): p. 123-93. 
119. Akinc, A., et al., Targeted delivery of RNAi therapeutics with endogenous and 
exogenous ligand-based mechanisms. Mol Ther, 2010. 18(7): p. 1357-64. 
120. Baratta, J.L., et al., Cellular organization of normal mouse liver: a histological, 
quantitative immunocytochemical, and fine structural analysis. Histochem Cell Biol, 
2009. 131(6): p. 713-26. 
121. Snoeys, J., et al., Species differences in transgene DNA uptake in hepatocytes after 
adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther, 2007. 
14(7): p. 604-12. 
122. Hak, S., et al., The effect of nanoparticle polyethylene glycol surface density on 
ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano, 
2012. 6(6): p. 5648-58. 
